

(19)

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 0 845 530 A2**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
03.06.1998 Bulletin 1998/23

(51) Int Cl.<sup>6</sup>: **C12N 15/12, C07K 14/47,  
C12N 5/10, A61K 38/17,  
A61K 38/20**

(21) Application number: **97309632.4**

(22) Date of filing: **28.11.1997**

(84) Designated Contracting States:  
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC  
NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: **29.11.1996 JP 333037/96**  
**21.01.1997 JP 20906/97**  
**14.11.1997 JP 329715/97**

(71) Applicant: **KABUSHIKI KAISHA HAYASHIBARA  
SEIBUTSU KAGAKU KENKYUJO  
Okayama-shi Okayama (JP)**

(72) Inventors:  
• **Yamamoto, Kozo**  
**Okayama-shi, Okayama (JP)**  
• **Okamoto, Iwao**  
**Okayama-shi, Okayama (JP)**  
• **Kurimoto, Masashi**  
**Okayama-shi, Okayama (JP)**

(74) Representative: **Daniels, Jeffrey Nicholas et al**  
**Page White & Farrer**  
**54 Doughty Street**  
**London WC1N 2LS (GB)**

(54) **Interferon gamma inducing factor**

(57) Disclosed are created stable polypeptides which are capable of inducing the production of interferon-gamma by immunocompetent cells. The present polypeptides contain specific amino acid sequences usually derived from the wild-type polypeptides, being capable of the production of interferon-gamma, by replacing the cysteine(s) with different amino acid(s). The present polypeptides possess a stability and an activity of inducing the production of IFN- $\gamma$  by immunocompetent cells, both of which are significantly higher than

those of the wild-type polypeptides. In addition to the activity, the present polypeptides can exhibit remarkable activities of inducing the formation of killer cells and enhancing their cytotoxicities. The present polypeptides are easily obtainable by the process according to the present invention using recombinant DNA techniques. Thus the present polypeptides are useful for agents to treat and/or prevent susceptible diseases such as viral diseases, infections, malignant tumors, and immunopathies.

**EP 0 845 530 A2**

## Description

The present invention relates to novel biologically active polypeptides, more particularly, artificially created polypeptides which are commonly capable of inducing the production of interferon-gamma (hereinafter abbreviated as "IFN- $\gamma$ ") by immunocompetent cells.

The present inventors successfully isolated some polypeptides which are capable of inducing the production of IFN- $\gamma$  by immunocompetent cells, as well as cloned cDNAs which encode the polypeptides (hereinafter called "the wild-type polypeptides"); the relating inventions are disclosed in Japanese Patent Kokai Nos.27,189/96 and 193,098/96 and Japanese Patent Application No.67,434/96. It is known that the wild-type polypeptides usually contain SEQ ID NOs:1-3 as consensus partial amino acid sequences, and that they usually possess properties of inducing the formation of killer cells and enhancing their cytotoxicities, in addition to the property of inducing production of IFN- $\gamma$ , a useful biologically active protein. Because of the properties, the use of the wild-type polypeptides as antiviral, antimicrobial, antitumor, and/or anti-immunopathic agents, etc. is in great expectation.

However, as described in Japanese Patent Application No.67,434/96 by the present applicant, there is the problem that natural cells commonly do not enable producing the wild-type polypeptide in desired amounts. The present inventors energetically investigated the cause, revealing that the wild-type polypeptides usually exist in the form of precursor exhibiting no biological activity in natural cells. The precursor has been proved to be converted into an active form by the action of converting enzymes such as interleukin-1 $\beta$  converting enzymes, which is described in Japanese Patent Application Nos.207,691/96 and 213,267/96 by the present applicant.

The wild-type polypeptides are probably instable, which would be involved in the above problem as another cause. Progress in recombinant DNA techniques of recent years have facilitated to remove and/or replace one or more amino acids in biologically active proteins to develop mutagenized polypeptides. However, even the progressed recombinant DNA techniques couldn't improve the stability of every protein with the inherent activity, unless taking trails and errors on the proteins individually.

In view of the foregoing, the first object of the present invention is to provide a polypeptide with significantly improved stability, while substantially retaining a biological activity of the wild-type polypeptide.

The second object of the present invention is to provide a process for producing the polypeptide.

The third object of the present invention is to provide a use of the polypeptide for a pharmaceuticals.

The present inventors energetically studied to attain the above objects, revealing that a polypeptide is more stable than the wild-type polypeptide, wherein the stable polypeptide contain an amino acid sequence derived either from a polypeptide containing the partial amino acid sequences of SEQ ID NOs:1-3 by replacing one or more of the cysteines with a different amino acid(s), or from the cysteine-replaced amino acid sequences by adding, removing and/or replacing one or more amino acids to and/or at position(s) excepting the position(s) where the cysteine(s) has been replaced; and that some of the stable polypeptides, in which the cysteine(s) have been replaced, exhibit an activity of inducing the production of IFN- $\gamma$  by immunocompetent cells significantly higher than the wild-type polypeptides. These polypeptides proved to be easily produced in a desired amount by using recombinant DNA techniques and to exhibit less toxicities. Based on the above, the present polypeptides were confirmed to be effectively used not only as an IFN- $\gamma$  inducer but also as a pharmaceutical.

The first object of the present invention is attainable by an isolated polypeptide which is capable of inducing the production of interferon-gamma by immunocompetent cells, said polypeptide containing either amino acid sequence wherein one or more cysteines are replaced with different amino acid(s) while leaving respective consensus sequences as shown in SEQ ID NOs:1-3 intact, or that wherein one or more amino acids are added, removed and/or replaced at one or more sites including those in the consensus sequences but excluding those of the replaced cysteine.

The second object of the present invention is attainable by a process for producing a polypeptide, which comprises the steps of culturing a cell containing a DNA encoding the present polypeptide to produce a polypeptide, and collecting the produced polypeptide from the resulting culture.

The third object of the present invention is attainable by an agent for susceptible diseases, which contains the present polypeptide as an effective ingredient.

FIG. 1 is the restriction map of a recombinant DNA "pCSHIGIF/MUT12" encoding a polypeptide according to the present invention.

FIG. 2 is the restriction map of a recombinant DNA "pCSHIGIF/WT" encoding the wild-type polypeptide from human origin.

FIG. 3 shows the time course of activity upon incubation of the polypeptides according to the present invention and the wild-type polypeptide, from human origin.

FIG. 4 is the restriction map of a recombinant DNA "pCSHIGIF/MUT21" encoding another polypeptide according to the present invention.

FIG. 5 is the restriction map of a recombinant DNA "pCSHIGIF/MUT25" encoding further another polypeptide according to the present invention.

FIG. 6 is the restriction map of a recombinant DNA "pCSHIGIF/MUT32" encoding further another polypeptide according to the present invention.

FIG. 7 is the restriction map of a recombinant DNA "pCSHIGIF/MUT41" encoding further another polypeptide according to the present invention.

FIG. 8 is the restriction map of a recombinant DNA "pCSHIGIF/MUT35" encoding further another polypeptide according to the present invention.

FIG. 9 is the restriction map of a recombinant DNA "pCSHIGIF/MUT42" encoding further another polypeptide according to the present invention.

FIG. 10 is the restriction map of a recombinant DNA "pCSMIGIF/MUT11" encoding further another polypeptide according to the present invention.

FIG. 11 is the restriction map of a recombinant DNA "pCSMIGIF/WT" encoding the wild-type polypeptide from mouse origin.

FIG. 12 shows the time course of activity upon incubation of the polypeptides according to the present invention and the wild-type polypeptide, from mouse origin.

FIG. 13 is the restriction map of a recombinant DNA "pCSMIGIF/MUT12" encoding further another polypeptide according to the present invention.

#### [Explanation of Symbols]

The symbol "CMV" indicates a cytomegalovirus promoter.

The symbol "IFNss" indicates a nucleotide sequence encoding the signal peptide of the subtype  $\alpha 2b$  of human interferon- $\alpha$ .

The symbols "IGIF/WT" and "mIGIF/WT" indicate cDNAs encoding any one of the wild-type polypeptides.

The symbols of "IGIF/MUT12", "IGIF/MUT21", "IGIF/MUT25", "IGIF/MUT32", "IGIF/MUT41", "IGIF/MUT35", "IGIF/MUT42", "mIGIF/MUT11" and "mIGIF/MUT12" indicate cDNAs each of which encodes one of the polypeptides according to the present invention.

The followings are preferred embodiments according to the present invention. The polypeptides according to the present invention include all of the polypeptides which is capable of inducing production of interferon-gamma by immunocompetent cells, wherein said polypeptides contain either amino acid sequence wherein one or more cysteines are replaced with different amino acid(s) while leaving respective consensus sequences as shown in SEQ ID NOs:1-3 intact, or that wherein one or more amino acids are added, removed and/or replaced at one or more sites including those in the consensus sequences but excluding those of the replaced cysteine. The different amino acids to replace the cysteine(s) are not restricted to any types, as far as the resulting polypeptide, containing an amino acid sequence replaced with the different amino acid(s), exhibits an activity of inducing production of IFN- $\gamma$  by immunocompetent cells in the presence or absence of an appropriate cofactor, as the wild-type polypeptides containing SEQ ID NOs:1-3 as consensus partial amino acid sequences, and a stability significantly higher than that of the wild-type polypeptides. The different amino acids include serine, threonine, alanine, valine, leucine, isoleucine, histidine, tyrosine, phenylalanine, tryptophan, and methionine, among which the most preferable amino acid is serine or alanine. Embodiments of the amino acid sequences, containing SEQ ID NOs:1-3 as consensus partial amino acid sequences, in which one or more cysteines are to be replaced with different amino acid(s) are the wild-type polypeptides containing the SEQ ID NO:4 or 5. The SEQ ID NO:4 contains cysteines at the 38th, 68th, 76th, and 127th positions from the N-terminus. The SEQ ID NO:5 contains cysteines at the 7th, 75th, and 125th positions.

The present polypeptides include those containing the amino acid sequence of any one of SEQ ID NOs:6-12, which are derived from the wild-type polypeptide containing SEQ ID NO:4, those containing the amino acid sequence of SEQ ID NO:13 or 14, which are derived from the wild-type polypeptide containing the amino acid sequence of SEQ ID NO:5, and those containing an amino acid sequence derived from any one of SEQ ID NOs:6-14 by adding, removing, and/or replacing one or more amino acids to and/or at position(s) excepting the positions where the cysteine(s) have been replaced while retaining the desired biological activities and stability. The wording "one or more amino acids" means the number of amino acids which conventional methods such as site-directed mutagenesis can usually add, remove or replace. The polypeptides containing any one of SEQ ID NOs:6-14 possess both stability and biological activities significantly higher than those of the wild-type polypeptides.

The present polypeptides can be produced by recombinant DNA techniques of: transforming appropriate host cells with DNAs encoding the present polypeptides to obtain a cell containing the DNAs, culturing the cells containing the DNAs to produce the polypeptides, and collecting the produced polypeptides from the resulting culture. The present invention additionally provides a process using the recombinant DNA techniques for producing the present polypeptides, by which the present polypeptides can be easily obtained in a desired amount.

The DNAs used in the present process include all of the DNAs encoding any one of the present polypeptides, which can be obtained by a method of either artificial mutagenesis of DNAs from natural sources or chemical synthesis.

An example of the former method is as follows: preparing a DNA with the nucleotide sequence of SEQ ID NO:25 or 28 encoding the amino acid sequence of SEQ ID NO:4 or 5, respectively, from a natural cell as a source, and then applying "overlap extension", a method reported in Robert M. Horton et al. *Methods in Enzymology*, Vol.217 (New York: Academic Press, Inc., 1993), pp.270-279, to the DNA to replace one or more codons for the cysteines in SEQ ID NO: 4 or 5 with codon(s) for different amino acid(s). The present DNAs include DNAs containing any one of the nucleotide sequence of SEQ ID NOs:15-21, derived from SEQ ID NO:25, SEQ ID NOs:22 and 23, derived from SEQ ID NO:28, the complementary nucleotide sequences to SEQ ID NOs:15-23, and others derived from these nucleotide sequences by replacing one or more of the nucleotides with different one(s) without altering the amino acid sequences encoded thereby. An example of the latter method is chemical synthesis, by which the present DNAs are obtainable in usual manner based on the nucleotide sequences of SEQ ID NOs:9-15. Once obtained by any method, the present DNAs can be easily amplified to a desired amount by using PCR.

Generally in this field, when allowing a DNA encoding a polypeptide to express in a host cell, to improve the expressing efficiency or the biological activities of the polypeptide expressed, one or more nucleotides in the DNA can be replaced with different ones, and an appropriate promoter(s) and/or enhancer(s) can be linked to the DNA. The present DNAs can be also altered similarly as such. For example, nucleotide sequences for recognition sites by appropriate restriction enzymes, initiation codons, termination codons, and/or appropriate signal peptides including the signal peptide of the subtype  $\alpha 2b$  of interferon- $\alpha$ , shown in SEQ ID NO:16, can be arbitrary linked to the 5'- and/or 3'-termini of any of the nucleotide sequences of SEQ ID NOs:9-15, unless the resulting polypeptides diminish the desired biological activities and stabilities.

The present DNAs can express the present polypeptides with improved stabilities and biological activities after introduced into appropriate host cells from microbial, vegetal, or animal origin, preferably, animal origin. The present DNAs can be introduced into the host cells in the form of recombinant DNAs. The recombinant DNAs usually comprise one of the present DNAs and one of autonomously replicable vectors, which are obtainable by conventional recombinant DNA techniques, once the present DNAs are obtained. Embodiments of the vectors into which the present DNAs can be inserted are plasmid vectors including pCD, pCDL-SR $\alpha$ , pKY4, pCDM8, pCEV4 and pME18S, which usually comprise nucleotide sequences suitable for expressing the present DNAs in hosts, e.g., promoters, enhancers, replication origins, terminators of transcription, splicing sequences, and/or selection markers. The use of vectors with a promoter such as a heat shock protein promoter or the interferon- $\alpha$  promoter disclosed by the present applicant in Japanese Patent Kokai No.163,368, enables to regulate the present DNAs expression in the transformants by external stimuli.

To insert the present DNAs into the vectors, any conventional method in this field can be used. For example, DNAs containing the present DNAs and the vectors as above are digested by restriction enzymes and/or ultrasonication before the resulting fragments from the present DNAs are ligated with the vector fragments. Digestion by the restriction enzymes, which act on specific nucleotides, preferably, *AclI*, *BamHI*, *BglII*, *BstXI*, *EcoRI*, *HindIII*, *NciI*, *PstI*, *SacI*, *SalI*, *SmaI*, *SpeI*, *XbaI*, *XhoI*, etc., facilitate to ligate the DNA fragments with the vector fragments. When ligating the DNA fragments with the vector fragments, they are, if necessary, first annealed, and then treated with a DNA ligase *in vivo* or *in vitro*. The recombinant DNAs thus obtained can be unlimitedly replicated in hosts from microbial or animal origin.

The recombinant DNAs can be introduced into host cells suitable to produce the present polypeptides. Whereas any cells conventionally used as host cells in this field can be used in the present invention, the host cells from yeast or mammalian origin are more preferable when the polypeptides produced are used for pharmaceuticals. Embodiments of the host cells from mammalian origin are epithelial, interstitial, and hemopoietic cells from human, monkey, mouse, and hamster, which include 3T3 cells, C127 cells, CHO cells, CV-1 cells, COS cells, HeLa cells, MOP cells, and their mutants. To introduce the present DNAs into the hosts, any conventional methods can be used, e.g., DEAE-dextran method, calcium phosphate transfection method, electroporation method, lipofection method, microinjection method, and viral infection method as using retrovirus, adenovirus, herpesvirus, and vaccinia virus, etc. To select clones producing the present polypeptides from the transformants, the transformants can be cultured before examining the resulting cultures for the present polypeptides produced. The recombinant DNA techniques using mammalian host cells are detailed in publications such as Toshio KUROKI, Masaru TANIGUCHI and Mitsuo OSHIMURA eds., *Jikken-Igaku-Bessatsu, Saibo-Kogaku Handbook* (The handbook for the cell engineering), (Tokyo, Japan: Yodosha Co., Ltd., 1992), and Takashi YOKOTA and Kenichi ARAI eds., *Jikken-Igaku-Bessatsu, Biomanual Series 3, Idenshi-Cloning-Jikken-Ho* (The experimental methods for the gene cloning), (Tokyo, Japan: Yodosha Co., Ltd., 1993).

The transformants thus obtained, cells containing the present DNAs, can produce the present polypeptides intracellularly and/or extracellularly when cultured in culture media. For the culture media, any conventional ones used for transformants can be used. The culture media generally comprise: buffers as a base; inorganic ions such as sodium ion, potassium ion, calcium ion, phosphoric ion, and chloric ion; micronutrients, carbon sources, nitrogen sources, amino acids and vitamins, which can be used depending on metabolic abilities of the cells; and sera, hormones, cell growth factors, and cell adhesion factors, which are used if necessary. Examples of the culture media are 199 medium, DMEM medium, Ham's F12 medium, IMDM medium, MCDB 104 medium, MCDB 153 medium, MEM medium, RD

medium, RITC 80-7 medium, RPMI-1630 medium, RPMI-1640 medium, and WAJC 404 medium. Culturing the present transformants under the following conditions can generate cultures containing the present polypeptides: inoculating the present transformants into the culture media to give a cell density of  $1 \times 10^4$  -  $1 \times 10^7$  cells/ml, more preferably,  $1 \times 10^5$  -  $1 \times 10^6$  cells/ml, and culturing the cells in suspension- or monolayer-cultures at about 37°C for 1-7 days, more preferably, 2-4 days, if necessary, while replacing the culture media with fresh ones. The cultures thus obtained usually contain the present polypeptides in a concentration of about 1-100 µg/ml, which may vary depending on the types of the transformants or culture conditions used.

While the cultures thus obtained can be used intact as an IFN-γ inducer, they can be usually subjected to the steps for purifying the present polypeptides before use, following the steps of separating the present polypeptides from the cells or the cell debris by filtration, centrifugation, etc., and, if necessary, which may follow a step for disrupting the cells by ultrasonication, cell-lytic enzymes, and/or detergents. To purify the present polypeptides, conventional techniques in this field for purifying biologically active polypeptides can be arbitrarily used, e.g., salting-out, dialysis, filtration, concentration, fractional precipitation, ion-exchange chromatography, gel filtration chromatography, adsorption chromatography, isoelectric focusing chromatography, hydrophobic chromatography, reversed phase chromatography, affinity chromatography, gel electrophoresis and/or isoelectric focusing gel electrophoresis. The present polypeptides thus purified can be concentrated and/or lyophilized into liquids or solids depending on final uses. The monoclonal antibodies disclosed in Japanese Patent Application No.58,240/95 by the present applicant are extremely useful to purify the present polypeptides. Immunoaffinity chromatography using the antibodies can minimize the costs and the labors for obtaining the present polypeptides with a relatively high purity.

The present polypeptides can be usually added to media for culturing immunocompetent cells to produce INF-γ, or administered to humans to treat or prevent INF-γ susceptible diseases. In the case of producing INF-γ, lymphocytes separated from mammalian peripheral bloods or established cell lines such as HBL-38 cells, Mo cells ATCC CRL8066, Jurkat cells ATCC CRL8163, HuT78 cells ATCC TIB161, EL4 cells ATCC TUB39, L12-F4 cells, and mutant strains thereof are suspended in culture media containing 0.1 ng - 1 µg/ml, preferably, 1 - 100 ng/ml of the present polypeptides. Then, the cells are cultured by conventional methods for about 1-100 hours, if necessary, in the presence of T-cell stimulating agents such as mitogens, interleukin 2, and anti-CD3 antibodies, and while replacing the culture media with fresh ones. To collect the IFN-γ produced, the resulting cultures can be subjected to technique(s) appropriately selected from those conventional for purifying INF-γ, e.g., salting-out, dialysis, filtration, concentration, fractional precipitation, gel filtration chromatography, ion-exchange chromatography, hydrophobic chromatography, adsorption chromatography, affinity chromatography, isoelectric focusing chromatography, gel electrophoresis, and isoelectric focusing gel electrophoresis, etc.

Since the present polypeptides induce production of IFN-γ, agents for susceptible diseases containing the present polypeptides as an effective ingredient can induce production of IFN-γ in human bodies when administered to human, and can treat and/or prevent IFN-γ-susceptible diseases. When the present polypeptides have activities of enhancing cytotoxicities and/or inducing formation of killer cells such as NK cells, LAK cells (lymphokine-activated killer cells), and cytotoxic T cells, besides the IFN-γ inducing activity, as in Examples of the present invention, described below, the killer cells are also involved in treating and/or preventing susceptible diseases. Thus, the wording "susceptible diseases" as referred to in the present invention includes all of the diseases which can be treated and/or prevented by the direct or indirect action of IFN-γ and/or killer cells. The susceptible diseases are viral diseases including hepatitis, herpes, condyloma, and AIDS; infections including candidiasis, malaria, cryptococcoses, diseases caused by Yersinia infection, and tuberculosis; solid malignant tumors including renal carcinoma, mycosis fungoides, and chronic granulomatous diseases; blood-cell-derived malignant tumors including adult T cell leukemia, chronic myelogenous leukemia, and malignant lymphoma; immunopathies including allergies, rheumatism, and collagen diseases; and osteoporosis, etc. The present agents additionally containing interleukin 3 can completely treat or remit leukopenia and thrombopenia caused by radiation therapy or chemotherapy in treating malignant tumors, in addition to leukemia and myeloma.

Thus the present agents for susceptible diseases can be widely used for treating and/or preventing the aforesaid susceptible diseases in the forms of an antitumor agent, an antiviral agent, an antiseptic, an anti-immunopathic agent, a platelet-proliferating agent, and a leukocyte-proliferating agent, etc. The present agents can be usually processed into a liquid, paste, or solid form, containing 0.000001 - 100 w/w %, preferably, 0.0001 - 0.1 w/w % of the present polypeptides on a dry solid basis, while the form and the contents may vary depending on the uses and on the types and the symptoms of diseases to be treated and/or prevented.

The present agents can contain not only the present polypeptides solely but also other physiologically acceptable agents to form compositions, e.g., carriers, excipients, diluents, biological response modifiers and stabilizers, and if necessary, one or more other biologically active substances. The stabilizers can be proteins including serum albumins, and gelatins, saccharides including glucose, fructose, sucrose, maltose, lactose, trehalose, sorbitol, mannitol, maltitol, and lactitol, and buffers with phosphoric acid and/or succinic acid. Embodiments of the other biologically active substances are interferon-α, interferon-β, interferon-γ, interleukin 2, interleukin 3, interleukin 12, TNF-α, TNF-β, granulo-

cyte-colony stimulating factor, granulocyte macrophage-colony stimulating factor, carboquone, cyclophosphamide, aclarubicin, thiotepa, busulfan, anbitabine, cytarabine, 5-fluorouracil, 5-fluoro-1-(tetrahydro-2-furyl)uracil, methotrexate, actinomycin D, chromomycin A3, daunorubicin, doxorubicin, bleomycin, mitomycin C, vincristine, vinblastine, L-asparaginase, radio gold colloidal, Krestin®, picibanil, lentinan, and Maruyama vaccine.

Among the above agents, those containing interleukin 2 are particularly useful because the interleukin 2 effects as a cofactor when the present polypeptides induce production of IFN- $\gamma$  by immunocompetent cells. Thus the agents, additionally containing a natural or recombinant interleukin 2, can induce production of IFN- $\gamma$  in a desired level by even immunocompetent cells that scarcely produce IFN- $\gamma$  by the single action of present polypeptides.

The present agents additionally containing interleukin 12 can induce IFN- $\gamma$  in a particularly high level which the present polypeptides or interleukin 12 per se cannot achieve. In addition, since the present polypeptides can enhance the inhibitory action of interleukin 12 on production of immunoglobulin E antibodies, the present agents with interleukin 12 are useful as an anti-immunopathic agent to treat and/or prevent atopic diseases such as atopic asthma, atopic bronchial asthma, hay fever, allergic rhinitis, atopic dermatitis, vascular edema, and atopic dyspepsia. Because there occasionally exists interleukin 12 in human bodies while in a relatively-low level, then the present polypeptides can achieve the desired effects in the human bodies alone.

The present agents include those in a unit of dose form, which means a physically separated and formed medicament suitable for administration, and contains the polypeptides required for a daily dose or in a dose from 1/40 to several folds (up to 4 folds) of the daily dose. Embodiments of such medicaments are injections, liquids, powders, granules, tablets, capsules, sublinguals, ophthalmic solutions, nasal drops and suppositories.

The present agents can be used for administering orally or parenterally to patients and for activating antitumor cells *in vitro* as described below, both of which effect to treat and/or prevent the susceptible diseases. For example, the present agents are usually administered orally to patients or parenterally to patients' intradermal tissues, subcutaneous tissues, muscles or veins as observing the patients' symptoms and recuperations at a dose in the range of about 0.1 - 50 mg/shot, preferably, one  $\mu$ g/shot to one mg/shot of the present polypeptides 1-4 times/day or 1-5 times/week for one day or one year.

The present agents can be also useful in so called "antitumor immunotherapies" using interleukin 2. The antitumor immunotherapies are generally classified into (i) a method administering the interleukin 2 directly to the bodies of patients with malignant tumors, and (ii) a method introducing antitumor cells activated by the interleukin 2 *ex vivo* to the patients (adoptive immunotherapy), any of which can exert significantly improved effects when used with the present polypeptides. For example, in the method (i), the present polypeptides can be administered to patients at an dose ranging from about 0.1  $\mu$ g/shot/adult to one mg/shot/adult one to ten times simultaneously with or before the interleukin 2 administration. The dose of interleukin 2, which may vary depending on the types of the malignant tumors, the patients' symptoms and the dose of the present polypeptides, is usually in the range of 10,000 - 1,000,000 units/shot/adult. In the method (ii), to the media for culturing mononuclear cells or lymphocytes collected from patients with malignant tumors in the presence of the interleukin 2, the present polypeptides can be usually added with an amount of about 0.1 ng - 1  $\mu$ g per  $1 \times 10^6$  of the cell. After the cells are cultured for a prescribed period of time, NK cells or LAK cells are collected from the resulting cultures to be returned to the patients' bodies. Diseases as targets for the present antitumor immunotherapies are: solid malignant tumors such as colonic cancer, rectal cancer, gastric cancer, thyroid carcinoma, cancer of tongues, bladder carcinoma, choriocarcinoma, hepatoma, prostatic cancer, carcinoma uteri, laryngeal, lung cancer, breast cancer, malignant melanoma, Kaposi's sarcoma, cerebral tumor, neuroblastoma, tumor of ovaries, testicular tumor, osteosarcoma, cancer of pancreas, renal cancer, hypernephroma, and hemangioendothelioma; and blood cell malignant tumors such as leukemia and malignant lymphoma, etc.

The present DNAs, encoding the present polypeptides, are also useful in so called "gene therapies". According to conventional techniques in the gene therapies, the present DNAs can be introduced into patients with IFN- $\gamma$ - and/or killer cell-susceptible diseases by direct injection after inserted into vectors derived from viruses such as retrovirus, adenovirus and adeno-associated virus, or after incorporated into cationic- or membrane fusible-liposomes. Alternatively, the present DNAs can be introduced into the patients by self-transplanting lymphocytes which have been collected from the patients before the DNAs have been introduced into. In adoptive immunotherapies with the gene therapies, the present DNAs can be introduced into effector cells similarly as using the conventional techniques. This can enhance cytotoxicities of the effector cells to tumor cells, resulting in improvement of the adoptive immunotherapy. In tumor vaccine therapy with the gene therapies, tumor cells from patients, into which the present DNAs can be introduced similarly as above, are self-transplanted after proliferated *ex vivo* up to give a desired cell number. The transplanted tumor cells act as vaccines in the patients to exert a improved antitumor immunity specific to the antigens. Thus the present DNAs exhibit remarkable effects in the gene therapies for diseases including viral diseases, microbial diseases, malignant tumors, and immunopathies. General procedures for the gene therapies are detailed in Takashi SHIMADA, Izumi SAITO and Keiya OZAWA eds., *Jikken-Igaku-Bessatsu, Biomanual UP Series, Idenshichiryō-no-Kisogijutsu* (Basic techniques for the gene therapy), (Tokyo, Japan: Yodosha Co., Ltd., 1996).

The following examples explain the present invention: Examples A-1 to A-9 describe preferred embodiments of

the polypeptides and the process for producing thereof according to the present invention, and Examples B-1 to B-5 describe the preferred embodiments of the agents for susceptible diseases according to the present invention. The techniques in Examples A-1 to A-9 are conventional ones used in this field, which are detailed in publications, e.g., Toshio KUROKI, Masaru TANIGUCHI and Mitsuo OSHIMURA eds., *Jikken-Igaku-Bessatsu, Saibo-Kogaku Handbook* (The handbook for the cell engineering), (Tokyo, Japan: Yodosha Co., Ltd., 1992), and Takashi YOKOTA and Kenichi ARAI eds., *Jikken-Igaku-Bessatsu, Biomanual Series 3, Idenshi-Cloning-Jikken-Ho* (The experimental methods for the gene cloning), (Tokyo, Japan: Yodosha Co., Ltd., 1993).

#### Example A-1

#### Production of polypeptide

#### Example A-1(a)

#### Construction of recombinant DNA

Genomic DNA was collected by conventional manner from BALL-1 cells, ATCC RCB0256, an established cell line derived from human acute lymphocytic leukemia, and oligonucleotides with the nucleotide sequences of 5'-ACACCTC-GAGCCACCATGGCCTTGACCTTTGCTTTAAC-3' as a sense primer (the sense primer 1) and of 5'-TTGCCAAAG-TAGCCCACAGAGCAGCTTG-3' as an antisense primer (the antisense primer 1) were chemically synthesized based on the nucleotide sequence for the signal peptide of the subtype  $\alpha 2b$  of human interferon- $\alpha$ , shown in SEQ ID NO:24, described in K. Henco et al. *Journal of Molecular Biology*, Vol.185, pp.227-260 (1985). In a 0.5 ml-reaction tube, one  $\mu$ g of the genomic DNA, 10  $\mu$ l of 10  $\times$  PCR buffer, one  $\mu$ l of 25 mM dNTP mix, and adequate amounts of the sense primer 1 and the antisense primer 1 were mixed, and sterilized distilled water was added to the mixture to give a volume of 99  $\mu$ l. To the mixture, one  $\mu$ l of 2.5 units/ $\mu$ l Pfu DNA polymerase was further added. The mixture was subjected to 30 cycles of incubations at 94°C, 60°C, and 72°C for one minute, respectively, to perform a PCR, resulting in obtaining a DNA fragment (the DNA fragment 1) which comprised the nucleotide sequence of SEQ ID NO:24, a site recognized by a restriction enzyme of *Xho*I, linked to the 5'-terminus of the SEQ ID NO:24, and a sequence of 1st-11th nucleotides in SEQ ID NO:25, linked to the 3'-terminus of the SEQ ID NO:24.

The recombinant DNA "pHIGIF", containing the nucleotide sequence of SEQ ID NO:25 encoding the wild-type polypeptide with the amino acid sequence of SEQ ID NO:4, was prepared according to the methods described in Japanese Patent Kokai No.193,098/96 by the present applicant. The wild type polypeptide, with the amino acid sequence of SEQ ID NO:4, contains partial amino acid sequences of SEQ ID NOs:1-3 in the regions of 16th-21st, 30th-35th, and 51st-55th amino acids. Oligonucleotides with the nucleotide sequences of 5'-CTGCTCTGTGGGCTACTTT-GGCAAGCTTGAATC-3' as a sense primer (the sense primer 2) and 5'-ACACGCGGCCGCTAGTCTTCGTTTT-GAACAG-3' as an antisense primer (the antisense primer 2) were chemically synthesized in usual manner based on SEQ ID NOs:25 and 26. In a 0.5 ml-reaction tube, one ng of the recombinant DNA "pHIGIF", 10  $\mu$ l of 10  $\times$  PCR buffer, one  $\mu$ l of 25 mM dNTP mix and adequate amounts of the sense primer 2 and the antisense primer 2 were mixed, and then sterilized distilled water was added to the mixture to give a volume of 99  $\mu$ l. To the mixture, one  $\mu$ l of 2.5 units/ $\mu$ l Pfu DNA polymerase was further added. The mixture was subjected to 30 cycles of incubations at 94°C, 60°C and 72°C for one minute, respectively, to perform a PCR, resulting in obtaining a DNA fragment (the DNA fragment 2) which comprised the nucleotide sequence of SEQ ID NO:25, a termination codon of 5'-TAG-3' and a site recognized by a restriction enzyme of *Not*I, linked to the 5'-terminus of the SEQ ID NO:25, and a sequence of 57th-69th nucleotides in SEQ ID NO:24, linked to the 3'-terminus of the SEQ ID NO:25.

In a 0.5 ml-reaction tube, one ng of the DNA fragments 1 and 2 each, 10  $\mu$ l of 10  $\times$  PCR buffer, and one  $\mu$ l of 25 mM dNTP mix were mixed, and sterilized distilled water was added to the mixture to give a volume of 99  $\mu$ l. The mixture was incubated at 94°C for 3 minutes and slowly cooled to 37°C, and incubated at the temperature for 15 minutes. The mixture was given one  $\mu$ l of 2.5 units/ $\mu$ l Pfu DNA polymerase and slowly heated to 72°C, and then incubated at the temperature for 2 minutes. After added adequate amounts of the sense primer 1 and the antisense primer 2, the mixture was subjected to 30 cycles of incubations at 94°C for one minute, at 60°C for one minute, and at 72°C for 30 seconds, to perform a PCR, resulting in obtaining a DNA fragment (the DNA fragment 3) which comprised the nucleotide sequence of SEQ ID NO:26.

An oligonucleotide with the nucleotide sequence of 5'-CTCTGTGAAGTCTGAGAAAATTTCAACTC-3', as a mutagenic sense primer to replace the 283rd nucleotide of guanine in SEQ ID NO:26 with a cytosine, was chemically synthesized by usual manner. A PCR was performed similarly as that for obtaining the DNA fragment 1, but using the DNA fragment 3 as a template and the mutagenic sense primer for the sense primer 1. The PCR resulted in obtaining a DNA fragment (the DNA fragment 4) which comprised a nucleotides sequence identical to 276th-570th nucleotides in SEQ ID NO:26 except for the 287th nucleotide replaced with a cytosine.



An oligonucleotide with the nucleotide sequence of 5'-GAGTTGAAATTTCTCAGACTTCACAGAG-3', as a mutagenic antisense primer to replace the 287th nucleotide of guanine in SEQ ID NO:26 with a cytosine, was chemically synthesized by usual manner. A PCR was performed similarly as that for obtaining the DNA fragment 2, but using the DNA fragment 3 as a template and the mutagenic antisense primer for the antisense primer 1. The PCR resulted in obtaining a DNA fragment (the DNA fragment 5) which comprised a nucleotides sequence identical to 1st-304th nucleotides in SEQ ID NO:26 except for the 287th nucleotide replaced with a cytosine.

A PCR was performed similarly as that for obtaining the DNA fragment 3, but using the DNA fragments 4 and 5 as templates, to obtain a DNA fragment (the DNA fragment 6) containing a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:6. The DNA fragment 6 comprised the nucleotide sequence of SEQ ID NO:15, the nucleotide sequence of SEQ ID NO:24 and a site recognized by a restriction enzyme *Xho*I, linked to the 5'-terminus of the SEQ ID NO:15, and a termination codon of the nucleotides of 5'-TAG-3' and a site recognized by a restriction enzyme *Not*I, linked to 3'-terminus of the SEQ ID NO:15.

After the DNA fragment 6 by restriction enzymes *Xho*I and *Not*I was cleaved to generate a DNA fragment of 555 bps, 25 ng of the generated DNA fragment was mixed with 10 ng of a plasmid vector "pCDM8", commercialized by Invitrogen Corporation, San Diego, USA, which had been cleaved by the *Xho*I and *Not*I, and then the mixture was incubated at 16°C for 30 minutes using a ligation kit "LIGATION KIT VERSION 2", commercialized by Takara Shuzo Co., Tokyo, Japan. By cloning, an autonomously replicable recombinant DNA "pCSHIGIF/MUT12" consisting of 4,494bp was obtained. As shown in FIG. 1, in the recombinant DNA "pCSHIGIF/MUT12", a cDNA "IGIF/MUT12" with the nucleotide sequence of SEQ ID NO:15 was linked to downstream of the nucleotide sequence "IFNss", encoding the signal peptide of the subtype  $\alpha 2b$  of human interferon- $\alpha$ . As shown in the accompanied amino acid sequence, the nucleotide sequence of SEQ ID NO:15 encodes the amino acid sequence of SEQ ID NO:6, derived from the wild-type polypeptide with SEQ ID NO:4 by replacing the cysteine at the 68th position.

For a control, an autonomously replicable recombinant DNA "pCSHIGIF/WT" was prepared similarly as above excepting the DNA fragment 6 replaced with the DNA fragment 3. As shown in FIG. 2, in the recombinant DNA "pCSHIGIF/WT", a cDNA "IGIF/WT" with the nucleotide sequence of SEQ ID NO:25, encoding the wild-type polypeptide, was linked to downstream of the nucleotide sequence "IFNss", encoding the signal peptide of subtype  $\alpha 2b$  of human interferon- $\alpha$ .

#### Example A-1(b)

##### Production of polypeptide by transformant

The recombinant DNA "pCSHIGIF/MUT12", obtained in Example A-1(a), was introduced by conventional competent-cell method into an *Escherichia coli* strain "MC1061/P3", commercialized by Invitrogen Corporation, San Diego, USA, to obtain a transformant. The transformant was cultured in L medium (pH 7.2) containing 20  $\mu$ g/ml ampicillin and 10  $\mu$ g/ml tetracycline at 37°C for 18 hours under shaking conditions. The resulting culture was centrifuged to separate the cells, and the separated cells were subjected to conventional alkali-SDS method to extract the recombinant DNA.

2.5 ml of DME medium (pH 7.4) supplemented with 10 v/v % fetal bovine serum was put into each well of six-well microplates, and  $1.8 \times 10^5$  cells of COS-1, ATCC CRL1650, an established cell line derived from African green monkey kidney, was inoculated into each well. The microplates were incubated at 37°C for 24 hours in a 5 v/v % CO<sub>2</sub> incubator. After the incubation, the media were removed, and the wells were washed with DME medium containing 50 mM Tris-HCl buffer (pH 7.4). To each well, 1.8 ml of DME medium containing 2.8  $\mu$ g/ml of the recombinant DNA obtained above, 50 mM Tris-HCl buffer (pH 7.4), 0.4 mg/ml DEAE-dextran and 0.1 mM chloroquine was added, and the microplates were incubated at 37°C for 4 hours in a 5 v/v % CO<sub>2</sub> incubator. After the incubation, the media were removed, and 2.5 ml of 10 mM phosphate buffer (pH 7.4) containing 10 v/v % dimethylsulfoxide and 140 mM NaCl was added to each well, and then the microplates were stood at ambient temperature for 2 minutes. After the standing, the buffers were removed, and the wells were washed with DME medium containing 50 mM Tris-HCl buffer (pH 7.4). To each well, 2.5 ml of a culture medium "COS MEDIUM", commercialized by COSMOBIO Co., Ltd., Tokyo, Japan, was added, and the microplates were incubated at 37°C for 3 days in a 5 v/v % CO<sub>2</sub> incubator to culture the cells. The resulting culture was analyzed by Western blotting using the monoclonal antibody described in Japanese Patent Kokai No.231,598/96. The analysis proved that the present polypeptide, capable of inducing production of IFN- $\gamma$  by immunocompetent cells and containing an amino acid sequence derived from SEQ ID NO:4 by replacing the cysteine at 68th position with a serine, was produced in the culture in an amount of about 20 ng/ml.

As a control experiment, the recombinant DNA "pCSHIGIF/WT" obtained in Experiment A-1(a) was treated similarly as the recombinant DNA "pCSHIGIF/MUT12". Consequently, the wild-type polypeptide capable of inducing production of IFN- $\gamma$  was produced in the culture in an amount of about one ng/ml. This yield was no more than 5% of that obtained by using the recombinant DNA "pCDHIGIF/MUT12". This indicates that the polypeptide according to the present invention, in this Example, is more stable and exhibits biological activities higher than the wild-type polypeptide.



Example A-1(c)Purification of polypeptide

The culture containing the present polypeptide that was obtained in Experiment A-1(b) was centrifuged to collect a supernatant. After the supernatant was fed to a column, which was packed with a gel for immunoaffinity chromatography using the monoclonal antibody, prepared according to the methods disclosed in Japanese Patent Kokai No. 231,598/96 by the present applicant, and preliminarily washed with phosphate-buffered saline (hereinafter abbreviated as "PBS"), a fresh PBS was run through the column to wash, and then 0.1 M glycine-HCl buffer (pH 2.5) containing one M NaCl was run to elute. From the eluted fractions, those containing the polypeptide capable of inducing production of IFN- $\gamma$  by immunocompetent cells were collected. The collected fractions were dialyzed against PBS at 4°C for 18 hours, and then concentrated by membrane-filtration followed by lyophilization to obtain a solid polypeptide with a purity of about 95 % or higher and a recovery of about 50 % to the culture of the starting material. In parallel, the culture containing the wild-type polypeptide, obtained by using the recombinant DNA "pCSHIGIF/WT", was purified similarly as above for a control in analyzing the physicochemical properties as described below.

Example A-1(d)Molecular weight

SDS-Polyacrylamide gel electrophoresis of the polypeptide in Example A-1(c) in the presence of 2 w/v % dithiothreitol as a reducing agent, according to the method described in U. K. Laemli, *Nature*, Vol.227, pp.680-685 (1970), exhibited a main band of a protein capable of inducing IFN- $\gamma$  at a position corresponding to a molecular weight of about 18,000-19,500 daltons. The molecular weight markers used were bovine serum albumin (67,000 daltons), ovalbumin (45,000 daltons), carbonic anhydrase (30,000 daltons), soy bean trypsin inhibitor (20,100 daltons), and  $\alpha$ -lactalbumin (14,000 daltons). Example A-1(e)

N-Terminal amino acid sequence

Conventional analysis using a protein sequencer "MODEL 473A", commercialized by Perkin-Elmer Corp., Norwalk, USA, revealed that the polypeptide in Example A-1(c) had the amino acid sequence of SEQ ID NO:27 in the N-terminal region. Example A-1(f)

Stability

The present polypeptide or the wild-type polypeptide, in Example A-1(c), was dissolved in a culture medium "COS MEDIUM", commercialized by COSMOBIO Co., Ltd., Tokyo, Japan, to give about 10 ng/ml, and the solution was incubated at 40°C for 24 hours. After 0, 0.5, 1, 2, 4, 6, 8, 12, or 24 hours from starting the incubation, a portion of each solution was sampled. The samples were individually assayed on IFN- $\gamma$  inducing activity, according to the methods described below, in Example A-1(g), to study the time course of the activity upon the incubation. Percentage (%) of the residual activity at every point was calculated based on the activity at the starting point. The results are in FIG. 3.

As shown in FIG. 3, the polypeptide in this Example was more stable and retained the activity longer than the wild-type polypeptide. This evidences that the amino acid replacement used in this Example can effectively improve the stability of the wild type polypeptide without reducing the biological activities.

Example A-1(g)Production of IFN- $\gamma$  by immunocompetent cells

KG-1 cells, ATCC CCL246, an established cell line derived from human acute myelogenous leukemia, were inoculated into RPMI-1640 medium (pH 7.4) with no sera to give a density of  $3 \times 10^5$  cells/ml and cultured at 37°C for 4 days in a 5 v/v % CO<sub>2</sub> incubator. The cultured cells were collected and suspended to give a density of  $3 \times 10^6$  cells/ml in RPMI-1640 medium (pH 7.4) supplemented with 10 v/v % fetal bovine serum. 0.1 ml of the cell suspension was put into each well of 96-well microplates, and 0.1 ml of a solution containing the present polypeptide or the wild-type polypeptide, obtained in Example A-1(c), which had been diluted appropriately, was added to each well. Thereafter, the cells were cultured at 37°C for 24 hours in a 10 v/v % CO<sub>2</sub> incubator. 0.1 ml of supernatants of the cultures were collected from the wells and examined on productions of IFN- $\gamma$  by conventional enzyme-immunoassay. As a blank, an experiment was taken in parallel identically as above but using no polypeptides. Table 1 shows the results. The pro-

ductions of IFN- $\gamma$  in Table 1 were expressed with international units (IU), calculated based on the IFN- $\gamma$  standard Gg23-901-530, obtained from the International Institute of Health, USA.

Table 1

Polypeptide concentration, ng/ml	Production of IFN- $\gamma$ , IU/ml*
0	0 (0)
0.1	0.7 (0.6)
0.2	3.0 (2.4)
0.4	8.1 (7.4)
0.8	20.0 (18.9)
1.0	30.0 (25.9)

\* ) Value in parentheses represents the production of IFN- $\gamma$  when using the wild-type polypeptide.

Table 1 indicates that the present polypeptide acted on KG-1, an immunocompetent cell, to induce the production of IFN- $\gamma$ . The IFN- $\gamma$  production was equal to or higher than that induced by the wild-type polypeptide.

#### Example A-1(h)

#### Enhancement of cytotoxicity of NK cells

A fresh blood was collected from a healthy donor by using a syringe containing heparin, and the blood was diluted with the equal volume of PBS. The diluted blood was overlaid on FICOLL and centrifuged to obtain high-density lymphocytes. The lymphocytes were suspended to give a density of  $1 \times 10^6$  cells/ml in RPMI-1640 medium (pH 7.2) containing 10  $\mu$ g/ml kanamycin,  $5 \times 10^{-5}$  M 2-mercaptoethanol and 10 v/v % fetal bovine serum. 0.5 ml of the cell suspension was put into each well of 12-well microplates. To each well, the present polypeptide or the wild-type polypeptide, obtained in Example A-1(c), in 1.5 ml solution was added after appropriately diluted with a fresh preparation of the medium, and 0.5 ml of a fresh preparation of the medium with or without 50 units/ml of a recombinant human interleukin 2 was further added. Thereafter, the cells were cultured at 37°C for 24 hours in a 5 v/v % CO<sub>2</sub> incubator. The cultured cells were washed with PBS to obtain cultured lymphocytes containing NK cells as effector cells.

K-562 cells, ATCC CCL243, an established cell line derived from human chronic myelogenous leukemia, as target cells sensitive to NK cells, were labelled with <sup>51</sup>Cr by a conventional method, and  $1 \times 10^4$  cells of the labelled cells were put into each well of 96-well microplates. To the wells, the cultured lymphocytes obtained above were added to give the ratios of 2.5:1, 5:1 and 10:1 between the effector and the target cells, before cultured at 37°C for 4 hours in a 5 v/v % CO<sub>2</sub> incubator. Thereafter, the culture supernatants were examined on the radioactivity by conventional manner to estimate the number of killed cells. Percentage (%) of the killed cells to the target cells tested in each system was calculated to evaluate the cytotoxicity. Table 2 shows the results.

Table 2

Concentration of Polypeptide, pM*	Concentration of Interleukin 12, unit/ml	Cytotoxicity, %**		
		[Effector Cells] : [Target Cells]		
		2.5:1	5:1	10:1
0	0	22 (22)	35 (35)	65 (65)
0	10	30 (30)	48 (48)	73 (73)
0.5	0	25 (23)	41 (36)	65 (66)
0.5	10	31 (32)	54 (50)	69 (75)
5	0	28 (25)	49 (39)	66 (68)
5	10	36 (35)	58 (52)	79 (78)
50	0	30 (29)	53 (47)	77 (73)
50	10	42 (41)	62 (59)	82 (85)
500	0	33 (37)	56 (50)	84 (83)
500	10	57 (52)	78 (70)	96 (93)

NOTE) \*: "pM" means a molarity of  $10^{-12}$  M. \*\*: Value in parentheses represents the cytotoxicity exhibited when using the wild-type polypeptide.

As shown in Table 2, the present polypeptide enhanced the cytotoxicity of NK cells, and the enhancement was equal to or higher than that of the wild-type polypeptide. The enhancement was augmented by the co-existing of interleukin 2.

Example A-1(i)

Induction of LAK cell formation

5        Cultured lymphocytes containing LAK cells as effector cells were prepared by a procedure similar as in Example A-1(g) excepting the culturing time replaced with 72 hours. Raji cells, ATCC CCL86, an established cell line derived from human Burkitt lymphoma, as target cells non-sensitive to NK cells, was labelled with  $^{51}\text{Cr}$  according to the conventional method.  $1 \times 10^4$  of the labelled cells were put into each well of 96-well microplates, and the cultured lymphocytes were added to the wells to give the ratios of 5:1, 10:1, and 20:1 between the effector and the target cells, before cultured at  $37^\circ\text{C}$  for 4 hours in a 5 v/v %  $\text{CO}_2$  incubator. Thereafter, similarly as in Example A-1(g), the culture supernatants were examined on the radioactivity to evaluate the cytotoxicity. Table 3 shows the results.

10

15

20

25

30

35

40

45

50

55

Table 3

Concentration of Polypeptide, pM*	Concentration of Interleukin 12, unit/ml	Cytotoxicity, %**		
		[Effector Cells] : [Target Cells]		
		5:1	10:1	20:1
0	0	11 (11)	21 (21)	34 (34)
0	10	15 (15)	28 (28)	38 (38)
0.5	0	14 (13)	24 (22)	34 (35)
0.5	10	18 (17)	32 (31)	42 (43)
5	0	16 (15)	26 (23)	37 (39)
5	10	21 (19)	36 (34)	50 (48)
50	0	22 (20)	41 (25)	49 (44)
50	10	26 (23)	52 (42)	56 (54)
500	0	27 (27)	44 (34)	61 (57)
500	10	33 (31)	59 (54)	72 (67)

NOTE) \*: "pM" means a molarity of  $10^{-12}$  M. \*\*: Value in parentheses represents the cytotoxicity exhibited when using the wild-type polypeptide.

As shown in Table 3, the present polypeptide induced the formation of LAK cells, and the induction was equal to or higher than that of the wild-type polypeptide. The induction was augmented by the co-existing of interleukin 2.

Example A-1(i)Acute toxicity test

5 The present polypeptide in Example A-1(c) was percutaneously, perorally or intraperitoneally administered to 8-week-old mice in usual manner. As a result, the LD<sub>50</sub> of the present polypeptide proved to be about one mg or higher per one kg of the body weight, independently of the administration routs. This evidences that the present polypeptide can be incorporated into pharmaceuticals for humans without anxiety.

Example A-2Production of polypeptide

15 An autonomously replicable recombinant DNA "pCSHIGIF/MUT21" containing the nucleotide sequence of SEQ ID NO:16 was obtained by a procedure similar as in Example A-1(a) but using the DNA fragment 6, obtained in Example A-1(a), as a template, and an oligonucleotide with the nucleotide sequence of 5'-CTGATTCTGACTCTAGATAATGC-3' and an oligonucleotide with the nucleotide sequence of 5'-GCATTATCTCTAGAGTCAGAATCAG-3', as a mutagenic sense and a mutagenic antisense primer, respectively, to replace the cysteine at 38th position in SEQ ID NO:4 with a serine. As shown in FIG. 4, in the recombinant DNA "pCSHIGIF/MUT21", a cDNA "IGIF/MUT21" encoding the amino acid sequence of SEQ ID NO:7 was linked to downstream of the nucleotide sequence "IFNss", encoding the signal peptide of the subtype  $\alpha 2b$  of human interferon- $\alpha$ .

20 The recombinant DNA was introduced into COS-1 cells similarly as in Example A-1(b) to obtain a transformant. Culturing the transformant produced the polypeptide with the amino acid sequence of SEQ ID NO:7 in an amount of about 50 ng per one ml of the culture. The culture was purified before analyzed on the physicochemical properties similarly as in Example A-1. As a result, the polypeptide in this Example proved to be similar to that in Example A-1 in the properties, i.e., the molecular weight, the N-terminal amino acid sequence, and the less toxicity. As shown in FIG. 3, the results of the analysis on stability, obtained according to the method in Example A-1(f), the present polypeptide in this Example was more stable than the wild-type polypeptide. These results evidence that the amino acid replacement used in this Example can effectively improve the stability of the wild type polypeptide without reducing the biological activities.

Example A-3Production of polypeptide

35 An autonomously replicable recombinant DNA "pCSHIGIF/MUT25" containing the nucleotide sequence of SEQ ID NO:17 was obtained by a procedure similar as in Example A-1(a) but using the DNA fragment 6, obtained in Example A-1(a), as a template, and an oligonucleotide with the nucleotide sequence of 5'-CTTCTAGCTTCTGAAAAAGAGAGAG-3' and an oligonucleotide with the nucleotide sequence of 5'-CTCTCTCTTTTCAGAAGCTAGAAAG-3', as a mutagenic sense and a mutagenic antisense primer, respectively, to replace the cysteine at 127th position in SEQ ID NO:4 with a serine. As shown in FIG. 5, in the recombinant DNA "pCSHIGIF/MUT25", a cDNA "IGIF/MUT25" encoding the amino acid sequence of SEQ ID NO:8 was linked to downstream of the nucleotide sequence "IFNss", encoding the signal peptide of the subtype  $\alpha 2b$  of human interferon- $\alpha$ .

40 The recombinant DNA was introduced into COS-1 cells similarly as in Example A-1(b) to obtain a transformant. Culturing the transformant produced the polypeptide with the amino acid sequence of SEQ ID NO:4 in an amount of about 30 ng per one ml of the culture. The culture was purified before analyzed on the physicochemical properties similarly as in Example A-1. As a result, the polypeptide in this Example proved to be similar to that in Example A-1 in the properties, i.e., the molecular weight, the N-terminal amino acid sequence, and the less toxicity. As shown in FIG. 3, the results of the analysis on stability, obtained according to the method in Example A-1(f), the present polypeptide in this Example was more stable than the wild-type polypeptide. These results evidence that the amino acid replacement used in this Example can effectively improve the stability of the wild type polypeptide without reducing the biological activities.

Example A-4Production of polypeptide

55 An autonomously replicable recombinant DNA "pCSHIGIF/MUT32" containing the nucleotide sequence of SEQ

ID NO:18 was obtained by a procedure similar as in Example A-1(a) but using the cDNA "IGIF/MUT21" as a template, encoding the amino acid sequence of SEQ ID NO:7, in the recombinant DNA "pCSHIGIF/MUT21" obtained in Example A-2, and an oligonucleotide with the nucleotide sequence of 5'-CTTCTAGCTTCTGAAAAAGAGAGAG-3' and an oligonucleotide with the nucleotide sequence of 5'-CTCTCTCTTTTCAGAAGCTAGAAAG-3', as a mutagenic sense and a mutagenic antisense primer, respectively, to replace the cysteine at 127th position in SEQ ID NO:4 with a serine. As shown in FIG. 6, in the recombinant DNA "pCSHIGIF/MUT32", a cDNA "IGIF/MUT32" encoding the amino acid sequence of SEQ ID NO:9 was linked to downstream of the nucleotide sequence "IFNss", encoding the signal peptide of the subtype a2b of human interferon- $\alpha$ .

The recombinant DNA was introduced into COS-1 cells similarly as in Example A-1(b) to obtain a transformant. Culturing the transformant produced the polypeptide with the amino acid sequence of SEQ ID NO:9 in an amount of about 80 ng per one ml of the culture. The culture was purified before analyzed on the physicochemical properties similarly as in Example A-1. As a result, the polypeptide in this Example proved to be similar to that in Example A-1 in the properties, i.e., the molecular weight, the N-terminal amino acid sequence, and the less toxicity. As shown in FIG. 3, the results of the analysis on stability, obtained according to the method in Example A-1(f), the present polypeptide in this Example was more stable than the wild-type polypeptide. These results evidence that the amino acid replacement used in this Example can effectively improve the stability of the wild type polypeptide without reducing the biological activities.

#### Example A-5

##### Production of polypeptide

An autonomously replicable recombinant DNA "pCSHIGIF/MUT41" containing the nucleotide sequence of SEQ ID NO:19 was obtained by a procedure similar as in Example A-1(a) but using the cDNA "IGIF/MUT32" as a template, with the nucleotide sequence of SEQ ID NO:18, in the recombinant DNA "pCSHIGIF/MUT32" obtained in Example A-4, and an oligonucleotide with the nucleotide sequence of 5'-CAACTCTCTCCTCTGAGAACAA-3' and an oligonucleotide with the nucleotide sequence of 5'-TTGTTCTCAGAGGAGAGAGTTG-3', as a mutagenic sense and a mutagenic antisense primer, respectively, to replace the cysteine at 76th position in SEQ ID NO:4 with a serine. As shown in FIG. 7, in the recombinant DNA "pCSHIGIF/MUT41", a cDNA "IGIF/MUT41" encoding the amino acid sequence of SEQ ID NO:10 was linked to downstream of the nucleotide sequence "IFNss", encoding the signal peptide of the subtype a2b of human interferon- $\alpha$ .

The recombinant DNA was introduced into COS-1 cells similarly as in Example A-1(b) to obtain a transformant. Culturing the transformant produced the polypeptide with the amino acid sequence of SEQ ID NO:10 in an amount of about 6 ng per one ml of the culture. The culture was purified before analyzed on the physicochemical properties similarly as in Example A-1. As a result, the polypeptide in this Example proved to be similar to that in Example A-1 in the properties, i.e., the molecular weight, the N-terminal amino acid sequence, and the less toxicity. As shown in FIG. 3, the results of the analysis on stability, obtained according to the method in Example A-1(f), the present polypeptide in this Example was more stable than the wild-type polypeptide. These results evidence that the amino acid replacement used in this Example can effectively improve the stability of the wild type polypeptide without reducing the biological activities.

#### Example A-6

##### Production of polypeptide

An autonomously replicable recombinant DNA "pCSHIGIF/MUT35" containing the nucleotide sequence of SEQ ID NO:20 was obtained by a procedure similar as in Example A-1(a) but using the cDNA "IGIF/MUT21" as a template, encoding the amino acid sequence of SEQ ID NO:7, in the recombinant DNA "pCSHIGIF/MUT21" obtained in Example A-2, and an oligonucleotide with the nucleotide sequence of 5'-CTCTCCGCTGAGAACAAATTATTTCC-3' and an oligonucleotide with the nucleotide sequence of 5'-TTTGTCTCAGCGGAGAGAGTTG-3', as a mutagenic sense and a mutagenic antisense primer, respectively, to replace the cysteine at 76th position in SEQ ID NO:4 with an alanine. As shown in FIG. 8, in the recombinant DNA "pCSHIGIF/MUT41", a cDNA "IGIF/MUT35" encoding the amino acid sequence of SEQ ID NO:11 was linked to downstream of the nucleotide sequence "IFNss", encoding the signal peptide of the subtype  $\alpha$ 2b of human interferon- $\alpha$ .

The recombinant DNA was introduced into COS-1 cells similarly as in Example A-1(b) to obtain a transformant. Culturing the transformant produced the polypeptide with the amino acid sequence of SEQ ID NO:11 in an amount of about 60 ng per one ml of the culture. The culture was purified before analyzed on the physicochemical properties similarly as in Example A-1. As a result, the polypeptide in this Example proved to be similar to that in Example A-1 in



the properties, i.e., the molecular weight, the N-terminal amino acid sequence, and the less toxicity. As shown in FIG. 3, the results of the analysis on stability, obtained according to the method in Example A-1(f), the present polypeptide in this Example was more stable than the wild-type polypeptide. These results evidence that the amino acid replacement used in this Example can effectively improve the stability of the wild type polypeptide without reducing the biological activities.

#### Example A-7

##### Production of polypeptide

An autonomously replicable recombinant DNA "pCSHIGIF/MUT42" containing the nucleotide sequence of SEQ ID NO:21 was obtained by a procedure similar as in Example A-1(a) but using the cDNA "IGIF/MUT32" as a template, encoding the amino acid sequence of SEQ ID NO:18, in the recombinant DNA "pCSHIGIF/MUT32" obtained in Example A-4, and an oligonucleotide with the nucleotide sequence of 5'-CTCTCCGCTGAGAACAAAATTATTTCC-3' and an oligonucleotide with the nucleotide sequence of 5'-TTTGTCTCAGCGGAGAGAGTTG-3', as a mutagenic sense and a mutagenic antisense primer, respectively, to replace the cysteine at 76th position in SEQ ID NO:4 with an alanine. As shown in FIG. 9, in the recombinant DNA "pCSHIGIF/MUT42", a cDNA "IGIF/MUT42" encoding the amino acid sequence of SEQ ID NO:12 was linked to downstream of the nucleotide sequence "IFNss", encoding the signal peptide of the subtype  $\alpha 2b$  of human interferon- $\alpha$ .

The recombinant DNA was introduced into COS-1 cells similarly as in Example A-1(b) to obtain a transformant. Culturing the transformant produced the polypeptide with the amino acid sequence of SEQ ID NO:12 in an amount of about 30 ng per one ml of the culture. The culture was purified before analyzed on the physicochemical properties similarly as in Example A-1. As a result, the polypeptide in this Example proved to be similar to that in Example A-1 in the properties, i.e., the molecular weight, the N-terminal amino acid sequence, and the less toxicity. As shown in FIG. 3, the results of the analysis on stability, obtained according to the method in Example A-1(f), the present polypeptide in this Example was more stable than the wild-type polypeptide. These results evidence that the amino acid replacement used in this Example can effectively improve the stability of the wild type polypeptide without reducing the biological activities.

#### Example A-8

##### Production of polypeptide

A PCR was performed similarly as the PCR for obtaining the DNA fragment 1 in Example A-1(a) but using an oligonucleotide with the nucleotide sequence of 5'-CGGCCAAAGTTGCCACAGAGCAGCTTG-3', chemically synthesized, for the antisense primer 1. The PCR resulted in obtaining a DNA fragment (the DNA fragment 7) which comprised the nucleotide sequence of SEQ ID NO:24, a site recognized by a restriction enzyme *Xho*I, linked to the 5'-terminus of the SEQ ID NO:24, and a sequence of 1st-11th nucleotides in the nucleotide sequence of SEQ ID NO:28, linked to the 3'-terminus of the SEQ ID NO:24.

The recombinant DNA "pMGTG-1", containing the nucleotide sequence of SEQ ID NO:28 encoding the wild-type polypeptide with the amino acid sequence of SEQ ID NO:5, was prepared according to the methods described in Japanese Patent Kokai No.27,189/96 by the present applicant. The wild type polypeptide, with the amino acid sequence of SEQ ID NO:5, contains partial amino acid sequences of SEQ ID NOs:1, 2 and 3 in the parts consisting of 16th-21st, 29th-34th, and 50th-54th amino acids, respectively. Oligonucleotides with the nucleotide sequence of 5'-CTGCTCTGTGGGCAACTTTGGCCGACTTCACTG-3' as a sense primer (the sense primer 3) and 5'-ACACGCGGCCGCCTAACTTTGATGTAAGTTAG-3' as an antisense primer (the antisense primer 3) were chemically synthesized. Thereafter, a PCR was performed similarly as that for obtaining the DNA fragment 2 in Example A-1(a) but using the recombinant DNA "pMGTG-1", the sense primer 3 and the antisense primer 3 for the recombinant DNA "pHIGIF", the sense primer 2 and the antisense primer 2, respectively. The PCR resulted in obtaining a DNA fragment (the DNA fragment 8) which comprised the nucleotide sequence of SEQ ID NO:28, a termination codon of 5'-TAG-3' and a site recognized by a restriction enzyme *Nof*I, linked to the 3'-terminus of the SEQ ID NO:28, and a sequence of 57th-69th nucleotides in the nucleotide sequence of SEQ ID NO:24, linked to the 5'-terminus of the SEQ ID NO:28.

A PCR was performed similarly as that for obtaining the DNA fragment 3 in Example A-1(a) but using the DNA fragments 7 and 8 and the antisense primer 3, obtained above, for the DNA fragments 1 and 2 and the antisense primer 2, respectively. The PCR resulted in obtaining a DNA fragment (the DNA fragment 9) comprising the nucleotide sequence of SEQ ID NO:29.

A PCR was performed similarly as that for obtaining the DNA fragment 4 in Example A-1(a) but using the DNA fragment 9 for, the DNA fragment 3, the antisense primer 3 for the antisense primer 2, and an oligonucleotide with the

nucleotide sequence of 5'-GGCCGACTTCACGCTACAACC-3' for the mutagenic sense primer, to replace 103rd and 104th nucleotides of thymine and guanine in SEQ ID NO:29 with a guanine and cytosine, respectively. The PCR resulted in obtaining a DNA fragment (the DNA fragment 10) comprising a nucleotide sequence identical to 91st-570th nucleotides in SEQ ID NO:29 except for the 103rd and 104th replaced with a guanine and a cytosine, respectively.

A PCR was performed similarly as that for obtaining the DNA fragment 5 in Example A-1(a) but using the DNA fragment 9 for the DNA fragment 3, and an oligonucleotide with the nucleotide sequence of 5'-GGTTGTAGCGT-GAAGTCGGCC-3' for the mutagenic antisense primer, to replace 103rd and 104th nucleotides of thymine and guanine in SEQ ID NO:29 with a guanine and cytosine, respectively. The PCR resulted in obtaining a DNA fragment (the DNA fragment 11) comprising a nucleotide sequence identical to 1st-111th nucleotides in SEQ ID NO:29 except for the 103rd and 104th, replaced with a guanine and cytosine, respectively.

A PCR was performed similarly as that for obtaining the DNA fragment 3 in Example A-1(a) but using the DNA fragments 10 and 11 and the antisense primer 3, obtained above, for the DNA fragments 1 and 2 and the antisense primer, respectively. The PCR resulted in obtaining a DNA fragment (the DNA fragment 12) comprising the nucleotide sequence of SEQ ID NO:22, the nucleotide sequence of SEQ ID NO:24 and a site recognized by a restriction enzyme *Xho*I, linked to the 5'-terminus of the SEQ ID NO:22, and a termination codon of 5'-TAG-3' and a site recognized by a restriction enzyme *Not*I, linked to the 3'-terminus of the SEQ ID NO:22.

The DNA fragment 12 was treated similarly as the DNA fragment 6, according the procedure for obtaining the recombinant DNA "pCSHIGIF/MUT12" in Example A-1(a), to obtain a autonomously replicable recombinant DNA "pCSMIGIF/MUT11". As shown in FIG. 10, in the recombinant DNA "pCSMIGIF/MUT11", a cDNA "mIGIF/MUT11" with the nucleotide sequence of SEQ ID NO:22 was linked to downstream of the nucleotide sequence "IFNss", encoding the signal peptide of the subtype  $\alpha 2b$  of human interferon- $\alpha$ . As shown in the accompanied amino acid sequence, the SEQ ID NO:22 encodes an amino acid sequence derived from the wild type polypeptide with SEQ ID NO:5 by replacing the cysteine at the 7th position with an alanine.

For a control, an autonomously replicable recombinant DNA "pCSMIGIF/WT" was prepared similarly as the procedure for obtaining the recombinant DNA "pCSHIGIF/MUT12" but treating the DNA fragment 9 for the DNA fragment 6. As shown in FIG. 11, in the recombinant DNA "pCSMIGIF/WT", a cDNA "mIGIF/WT" with the nucleotide sequence of SEQ ID NO:28, encoding the wild-type polypeptide, was linked to downstream of the nucleotide sequence "IFNss", encoding the signal peptide of subtype  $\alpha 2b$  of human interferon- $\alpha$ .

#### Example A-8(b)

##### Production of polypeptide by transformant

According to the procedure for the production of the polypeptide in Example A-1(b) but using the recombinant DNA "pCSMIGIF/MUT12" for "pCSHIGIF/MUT11", the recombinant DNA was extracted, the DNA was introduced into COS-1 cells, and the COS-1 cells with the DNA was cultured to obtain a culture. The culture was analyzed by Western blotting using the monoclonal antibody described in Japanese Patent Kokai No.217,798/96 by the present applicant. The analysis proved that the present polypeptide capable of inducing production of IFN- $\gamma$  by immunocompetent cells, with the amino acid sequence derived from SEQ ID NO:5 by replacing the cysteine at 7th position with an alanine, was produced in the culture in an amount of about 20 ng/ml.

As a control, treating the recombinant DNA "pCSMIGIF/WT" similarly as above produced the wild-type polypeptide capable of inducing production of IFN- $\gamma$  by immunocompetent cells. The production of the wild-type polypeptide was significantly lower than that obtained by using "pCSMIGIF/MUT11", described above. This evidences that the present polypeptide in this Example is more stable and exhibits the biological activities higher than the wild-type polypeptide.

#### Example A-8(c)

##### Purification of polypeptide

The culture containing the present polypeptide, in Example A-8(b), was centrifuged to collect a supernatant. The supernatant was fed to a column packed with a gel for immunoaffinity chromatography using the monoclonal antibody, prepared by the method described in Japanese Patent Kokai No.217,798/96 by the present applicant, and preliminarily washed with PBS. After a fresh PBS was run through the column to wash, 35 mM ethylamine (pH 10.8) was run to elute. From the eluted fractions, those containing the polypeptide capable of inducing production IFN- $\gamma$  by immunocompetent cells were collected. The collected fractions were dialyzed against PBS at 4°C for 18 hours, and then concentrated by membrane-filtration followed by lyophilization to obtain a solid polypeptide with a purity of about 95 %. In parallel, the culture containing the wild-type polypeptide, obtained by using the recombinant DNA "pCSMIGIF/

WT<sup>a</sup>, was purified similarly as above for a control in analyzing the physicochemical properties as described below.

#### Example A-8(d)

##### 5 Molecular weight

SDS-Polyacrylamide gel electrophoresis of the present polypeptide in Example A-8(c), similarly as in Example A-1(d), exhibited a main band of polypeptide capable of inducing production at a position corresponding to a molecular weight of about 18,500-19,500 daltons.

#### 10 Example A-8(e)

##### N-Terminal amino acid sequence

15 By analyzing similarly as in Example A-1(e), the present polypeptide in Example A-8(c) was proved to contain the amino acid sequence of SEQ ID NO:30 in the N-terminus.

#### Example A-8(f)

##### 20 Stability

The present polypeptide or the wild-type polypeptide, in Example A-8(c), was dissolved in PBS containing 0.2 g/ml maltose, and the solution was incubated at 40°C for 24 hours. After 0, 3, 9, or 24 hours from starting the incubation, a portion of each solution was sampled. The samples were individually assayed on IFN- $\gamma$  inducing activity, according to the methods described below, in Example A-8(g), to study the time course of the activity upon the incubation. Percentage (%) of the residual activity at every point was calculated based on the activity at the starting point. The results are in FIG. 12.

As shown in FIG. 12, the present polypeptide in this Example was more stable and retained the activity longer than the wild-type polypeptide. This evidences that the amino acid replacement used in this Example can effectively improve the stability of the wild type polypeptide without reducing the biological activities.

#### Example A-8(g)

##### Production of IFN- $\gamma$ by immunocompetent cells

35 Splenocytes were collected from C3H/HeJ mice as immunocompetent cells. The splenocytes were suspended in RPMI-1640 medium supplemented with 10 v/v % fetal bovine serum. The suspensions were given the present polypeptide or the wild-type polypeptide, in Example A-8(a), in the presence or absence of concanavalin A or interleukin 2. Thereafter, the splenocytes were cultured before examined on productions of IFN- $\gamma$  by conventional enzyme-immunoassay to evaluate an inducing activity of production of IFN- $\gamma$ . The present polypeptide proved to act on the splenocytes, immunocompetent cells, to induce the production of IFN- $\gamma$ . The inducing activity of IFN- $\gamma$  production of the present polypeptide was equal to or higher than that of the wild-type polypeptide.

#### Example A-8(h)

##### 45 Acute toxicity test

The present polypeptide in Example A-8(a) was examined on the acute toxicity by the method in Example A-1(j). As a result, the LD<sub>50</sub> of the present polypeptide proved to be about one mg or higher per one kg of the body weight, independently of the administration routs. This evidences that the present polypeptide can be incorporated into pharmaceuticals for mammalian including humans without anxiety.

#### Example A-9

##### 55 Production of polypeptide

An autonomously replicable recombinant DNA "pCSMIGIF/MUT12" containing the nucleotide sequence of SEQ ID NO:23 was obtained by a procedure similar as in Example A-8(a) but using the DNA fragment 9, obtained in Example

A-8(a), as a template, and an oligonucleotide with the nucleotide sequence of 5'-GGACACTTCTT-GCTAGCCAAAAGG-3' and an oligonucleotide with the nucleotide sequence of 5'-CCTTTTGGCTAGCAAGAAAGT-GTCC-3', as a mutagenic sense and a mutagenic antisense primer, respectively, to replace the cysteine at 125th position in SEQ ID NO:5 with a serine. As shown in FIG. 13, in the recombinant DNA "pCSMIGIF/MUT12", a cDNA "mIGIF/MUT12" encoding the amino acid sequence of SEQ ID NO:14 was linked to downstream of the nucleotide sequence "IFNss", encoding the signal peptide of the subtype  $\alpha 2b$  of human interferon- $\alpha$ .

The recombinant DNA was introduced into COS-1 cells similarly as in Example A-1(b) to obtain a transformant. Culturing the transformant produced the polypeptide with the amino acid sequence of SEQ ID NO:14 in an amount of about 50 ng per one ml of the culture. The culture was purified before analyzed on the physicochemical properties similarly as in Example A-8. As a result, the polypeptide in this Example proved to be similar to that in Example A-8 in the properties, i.e., the molecular weight, the N-terminal amino acid sequence, and the less toxicity. As shown in FIG. 12, the results of the analysis on stability, obtained according to the method in Example A-8(f), the present polypeptide in this Example was more stable than the wild-type polypeptide. These results evidence that the amino acid replacement used in this Example can effectively improve the stability of the wild type polypeptide without reducing the biological activities.

### Example B-1

#### Solution

Any one of the present polypeptides purified in Examples A-1 to A-9 was dissolved in physiological saline containing one v/v % human serum albumin as a stabilizer to give a concentration of one mg/ml, and the solution was membrane-filtered in usual manner into a germ-free solution.

The solutions, with a satisfactory stability, can be used as an injection, an ophthalmic solution, and a collunarium for treating and/or preventing susceptible diseases such as malignant tumors, viral diseases, infections and immunopathies, of mammalian including human.

### Example B-2

#### Dry injection

One hundred mg of any one of the present polypeptides purified in Examples A-1 to A-9 was dissolved in 100 ml of physiological saline containing one w/v % gelatin as a stabilizer, and the solution was sterilized membrane-filtered in usual manner into a germ-free solution. One ml aliquotes of each of the sterilized solutions were distributed to vials, and lyophilized before sealing the vials with caps.

The products, with a satisfactory stability, can be used as a dry injection for treating and/or preventing susceptible diseases such as malignant tumors, viral diseases, infections, and immunopathies of mammalian including human.

### Example B-3

#### Ointment

"HI-BIS-WAKO 104", a carboxyvinylpolymer commercialized by Wako Pure Chemicals, Tokyo, Japan, and "TRE-HALOSE", a powdered crystalline trehalose commercialized by Hayashibara Co., Ltd., Okayama, Japan, were dissolved in sterilized distilled water to give concentrations of 1.4 w/w % and 2.0 w/w %, respectively. Any one of the present polypeptides purified in Examples A-1 to A-9 was mixed with the solution into homogeneity. Each of the homogenate was adjusted to pH 7.2 to obtain a paste containing about one mg/g of any one of the polypeptides.

The pastes, with a satisfactory spreadability and stability, can be used as an ointment for treating and/or preventing susceptible diseases such as malignant tumors, viral diseases, infections and immunopathies, of mammalian including human.

### Example B-4

#### Tablet

Any one of the purified polypeptides in Examples A-1 to A-9 and "LUMIN", [bis-4-(1-ethylquinoline)][ $\gamma$ -4'-(1-ethylquinoline)] pentamethionine cyanine, as a cell activator, were mixed with "FINETOSE", an anhydrous crystalline  $\alpha$ -maltose commercialized by Hayashibara Co., Ltd., Okayama, Japan, into homogeneity. Each of the homogenate was

processed with a conventional tablet machine into tablets, each of which weighed 200 mg and contained about one mg of any of the polypeptides and the LUMIN.

The tablets with a satisfactory swallowability, stability and cell-activating activity can be used as a tablet for treating and/or preventing susceptible diseases such as malignant tumors, viral diseases, infections and immunopathies, of mammalian including human.

#### Example B-5

##### Adoptive immunotherapeutic agent

Mononuclear cells were isolated from a peripheral blood of a patient with malignant lymphoma. The cells were suspended in RPMI-1640 medium supplemented with 10 v/v % human AB serum, preheated at 37°C, to give a density of  $1 \times 10^6$  cells/ml. To the cell suspension, any one of the present polypeptides in Examples A-1 to A-7 and a recombinant human interleukin 2 were added as adoptive immunotherapeutic agent to give concentrations of 10 ng/ml and 100 units/ml, respectively, before the cells were cultured at 37°C for one week in a 5 v/v % CO<sub>2</sub> incubator. Thereafter, the culture was centrifuged to collect LAK cells.

The LAK cells can exhibit so strong cytotoxicity to the lymphoma when returned to the patient, and an adoptive immunotherapy using the present agent can exert significantly higher effect than that using the interleukin 2 alone. Cytotoxic T cells obtained similarly as above excepting the mononuclear cells, replaced with tumor-invasive lymphocytes, also can effect as equivalent to that of the LAK cells, when returned to the patient. Thus the adoptive immunotherapeutic agent in this Example can be effectively applied to solid malignant tumors such as renal cancer, malignant melanoma, colonic cancer, rectal cancer, and lung cancer, besides malignant lymphomas.

IFN- $\gamma$  is well known to be involved in protection against infections of virus and bacteria, etc., inhibition of malignant tumors proliferation, regulation of immune system causing protection, and inhibition of immunoglobulin E antibodies production. And IFN- $\gamma$  is now in use for agents against human susceptible diseases, stating that the directions for the targeting diseases, uses, dosages, and safeness have been already established.

As described in a publication as Frances R. Balkwill, *Saitokain-To-Ganchiryo (Cytokines in Cancer Therapy)*, Yoshihiko WATANABE tr., (Tokyo, Japan: Tokoyo Kagaku Dojin Co., Ltd., 1991), therapies using killer cells such as NK cells and LAK cells that include antitumor immunotherapies are applied to human diseases, resulting in satisfactory effects as a whole. Recently, an intensive interest is taken in the involvement of the killer cells, which have cytotoxicities enhanced by cytokines, or which are formed induced by cytokines, in therapeutic effects. For example, T. Fujioka et al., *British Journal of Urology*, Vol.73, No.1, pp.23-31 (1994) describes that in an antitumor immunotherapy using both LAK cells and interleukin 2, the interleukin 2 induced formation of the LAK cells, resulting in remarkable effects against human cancer metastases without exhibiting serious toxicities and side effects.

Thus, it has been revealed that IFN- $\gamma$  or killer cells are involved in treatment and/or prevention of a variety of human diseases, and can contribute to cure or remission to the diseases. As shown in Examples A-1 to A-9, the present polypeptides induce the production of IFN- $\gamma$  by immunocompetent cells, enhance the cytotoxicity of NK cells, and induce the formation of LAK cells, indicating that the present agents for susceptible diseases can be administered to patients successively for a relatively-long period of time, and effect to treat and/or prevent diseases, in which IFN- $\gamma$  and/or killer cells are involved, without causing serious side effects.

#### [Effect of the invention]

As described above, the present invention is made based on the establishment of stable polypeptides capable of inducing production of IFN- $\gamma$  by immunocompetent cells. The polypeptides according to the present invention are the substances clarified on their amino acid sequence, and feature to retain the biological activities for a relatively-long period in actual use, because of the higher stability than that of the wild-type polypeptide. Thus the present polypeptides provide a variety of uses such as an IFN- $\gamma$  inducer for producing IFN- $\gamma$  in cell cultures and an agent for treating and/or preventing diseases sensitive to IFN- $\gamma$  in general, including viral diseases, infections, malignant tumors, and immunopathies. The agents with the present polypeptides additionally possessing properties of enhancing cytotoxicities and/or inducing formation of killer cells, as effective ingredients, can satisfactorily treat serious diseases such as malignant tumors.

Furthermore, the present polypeptides generally can induce a desired level of IFN- $\gamma$  with only a slight amount since they have so strong activity of inducing production of IFN- $\gamma$ . Because of little toxicity, the polypeptides wouldn't cause serious side effects even when administered with relatively-high doses. These give the present polypeptides an advantage of that they can induce a desired level of IFN- $\gamma$  rapidly without strictly control on the dosages in actual use. The polypeptides with these usefulness can be easily produced in a desired amount by the present process using recombinant DNA techniques.

The present invention is a significant invention which has a remarkable effect and gives a great contribution to this field.

While there has been described what is at present considered to be the preferred embodiments of the present invention, it will be understood the various modifications may be made therein, and it is intended to cover in the appended claims all such modifications as fall within the true spirits and scope of the invention.

5

10

15

20

25

30

35

40

45

50

55

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

NAME:KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU  
KENKYUJO

## (ii) TITLE OF INVENTION:POLYPEPTIDES

## (iii) NUMBER OF SEQUENCES:30

## (iv) ADDRESS:

(A) ADDRESSEE:KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU  
KENKYUJO

(B) STREET:2-3, 1-CHOME, SHIMOISHII

(C) CITY:OKAYAMA

(E) COUNTRY:JAPAN

(F) POSTAL CODE (ZIP):700

## (v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE:Floppy disk

(B) COMPUTER:IBM compatible

(C) OPERATING SYSTEM:PC-DOS/MS-DOS

## (vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: JP 333,037/96

(B) FILING DATE: November 29, 1996

(A) APPLICATION NUMBER: JP 20,906/97

(B) FILING DATE: January 21, 1997

(A) APPLICATION REFERENCE NO: JP 10,053,503

(B) FILING DATE: November 14, 1997

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:6 amino acids

(B) TYPE:amino acid

(D) TOPOLOGY:linear

## (ii) MOLECULE TYPE:peptide

## (xi) SEQUENCE DESCRIPTION:SEQ ID NO:1:

Asn Asp Gln Val Leu Phe

1

5

## (3) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:6 amino acids

(B) TYPE:amino acid

(D) TOPOLOGY:linear

## (ii) MOLECULE TYPE:peptide

## (xi) SEQUENCE DESCRIPTION:SEQ ID NO:2:

Phe Glu Asp Met Thr Asp

1

5

## (4) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:5 amino acids



(B) TYPE:amino acid  
 (D) TOPOLOGY:linear  
 (ii) MOLECULE TYPE:peptide  
 (xi) SEQUENCE DESCRIPTION:SEQ ID NO:3:

Met Tyr Lys Asp Ser  
 1 5

(5) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH:157 amino acids  
 (B) TYPE:amino acid  
 (D) TOPOLOGY:linear

(ii) MOLECULE TYPE:peptide

(xi) SEQUENCE DESCRIPTION:SEQ ID NO:4:

Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn  
 1 5 10 15  
 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp  
 20 25 30  
 Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile  
 35 40 45  
 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile  
 50 55 60  
 Ser Val Lys Cys Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile  
 65 70 75 80  
 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys  
 85 90 95  
 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys  
 100 105 110  
 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu  
 115 120 125  
 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu  
 130 135 140  
 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp  
 145 150 155

(6) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH:157 amino acids  
 (B) TYPE:amino acid  
 (D) TOPOLOGY:linear

(ii) MOLECULE TYPE:peptide

(xi) SEQUENCE DESCRIPTION:SEQ ID NO:5:

Asn Phe Gly Arg Leu His Cys Thr Thr Ala Val Ile Arg Asn Ile Asn  
 1 5 10 15  
 Asp Gln Val Leu Phe Val Asp Lys Arg Gln Pro Val Phe Glu Asp Met  
 20 25 30  
 Thr Asp Ile Asp Gln Ser Ala Ser Glu Pro Gln Thr Arg Leu Ile Ile  
 35 40 45  
 Tyr Met Tyr Lys Asp Ser Glu Val Arg Gly Leu Ala Val Thr Leu Ser  
 50 55 60  
 Val Lys Asp Ser Lys Met Ser Thr Leu Ser Cys Lys Asn Lys Ile Ile  
 65 70 75 80  
 Ser Phe Glu Glu Met Asp Pro Pro Glu Asn Ile Asp Asp Ile Gln Ser  
 85 90 95  
 Asp Leu Ile Phe Phe Gln Lys Arg Val Pro Gly His Asn Lys Met Glu  
 100 105 110

Phe Glu Ser Ser Leu Tyr Glu Gly His Phe Leu Ala Cys Gln Lys Glu  
 115 120 125  
 Asp Asp Ala Phe Lys Leu Ile Leu Lys Lys Lys Asp Glu Asn Gly Asp  
 130 135 140  
 Lys Ser Val Met Phe Thr Leu Thr Asn Leu His Gln Ser  
 145 150 155

## (7) INFORMATION FOR SEQ ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:157 amino acids

(B) TYPE:amino acid

(D) TOPOLOGY:linear

## (ii) MOLECULE TYPE:peptide

## (xi) SEQUENCE DESCRIPTION:SEQ ID NO:6:

Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn  
 1 5 10 15  
 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp  
 20 25 30  
 Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile  
 35 40 45  
 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile  
 50 55 60  
 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile  
 65 70 75 80  
 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys  
 85 90 95  
 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys  
 100 105 110  
 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu  
 115 120 125  
 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu  
 130 135 140  
 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp  
 145 150 155

## (8) INFORMATION FOR SEQ ID NO:7:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:157 amino acids

(B) TYPE:amino acid

(D) TOPOLOGY:linear

## (ii) MOLECULE TYPE:peptide

## (xi) SEQUENCE DESCRIPTION:SEQ ID NO:7:

Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn  
 1 5 10 15  
 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp  
 20 25 30  
 Met Thr Asp Ser Asp Ser Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile  
 35 40 45  
 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile  
 50 55 60  
 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile  
 65 70 75 80  
 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys  
 85 90 95  
 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys  
 100 105 110  
 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu

115 120 125  
 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu  
 130 135 140  
 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp  
 145 150 155

## (9) INFORMATION FOR SEQ ID NO:8:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:157 amino acids

(B) TYPE:amino acid

(D) TOPOLOGY:linear

## (ii) MOLECULE TYPE:peptide

## (xi) SEQUENCE DESCRIPTION:SEQ ID NO:8:

Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn  
 1 5 10 15  
 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp  
 20 25 30  
 Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile  
 35 40 45  
 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile  
 50 55 60  
 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile  
 65 70 75 80  
 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys  
 25 85 90 95  
 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys  
 100 105 110  
 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Ser Glu  
 115 120 125  
 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu  
 30 130 135 140  
 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp  
 145 150 155

## (10) INFORMATION FOR SEQ ID NO:9:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:157 amino acids

(B) TYPE:amino acid

(D) TOPOLOGY:linear

## (ii) MOLECULE TYPE:peptide

## (xi) SEQUENCE DESCRIPTION:SEQ ID NO:9:

Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn  
 1 5 10 15  
 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp  
 45 20 25 30  
 Met Thr Asp Ser Asp Ser Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile  
 35 40 45  
 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile  
 50 55 60  
 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile  
 50 65 70 75 80  
 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys  
 85 90 95  
 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys  
 100 105 110  
 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Ser Glu  
 55 115 120 125

Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu  
 130 135 140  
 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp  
 145 150 155

## (11) INFORMATION FOR SEQ ID NO:10:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:157 amino acids

(B) TYPE:amino acid

(D) TOPOLOGY:linear

## (ii) MOLECULE TYPE:peptide

## (xi) SEQUENCE DESCRIPTION:SEQ ID NO:10:

Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn  
 1 5 10 15  
 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp  
 20 25 30  
 Met Thr Asp Ser Asp Ser Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile  
 35 40 45  
 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile  
 50 55 60  
 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Ser Glu Asn Lys Ile  
 65 70 75 80  
 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys  
 85 90 95  
 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys  
 100 105 110  
 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Ser Glu  
 115 120 125  
 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu  
 130 135 140  
 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp  
 145 150 155

## (12) INFORMATION FOR SEQ ID NO:11:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:157 amino acids

(B) TYPE:amino acid

(D) TOPOLOGY:linear

## (ii) MOLECULE TYPE:peptide

## (xi) SEQUENCE DESCRIPTION:SEQ ID NO:11:

Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn  
 1 5 10 15  
 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp  
 20 25 30  
 Met Thr Asp Ser Asp Ser Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile  
 35 40 45  
 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile  
 50 55 60  
 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Ala Glu Asn Lys Ile  
 65 70 75 80  
 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys  
 85 90 95  
 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys  
 100 105 110  
 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu  
 115 120 125  
 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu

130 135 140  
 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp  
 145 150 155

## (13) INFORMATION FOR SEQ ID NO:12:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:157 amino acids

(B) TYPE:amino acid

(D) TOPOLOGY:linear

## (ii) MOLECULE TYPE:peptide

## (xi) SEQUENCE DESCRIPTION:SEQ ID NO:12:

Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn  
 1 5 10 15  
 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp  
 20 25 30  
 Met Thr Asp Ser Asp Ser Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile  
 35 40 45  
 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile  
 50 55 60  
 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Ala Glu Asn Lys Ile  
 65 70 75 80  
 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys  
 85 90 95  
 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys  
 100 105 110  
 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Ser Glu  
 115 120 125  
 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu  
 130 135 140  
 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp  
 145 150 155

## (14) INFORMATION FOR SEQ ID NO:13:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:157 amino acids

(B) TYPE:amino acid

(D) TOPOLOGY:linear

## (ii) MOLECULE TYPE:peptide

## (xi) SEQUENCE DESCRIPTION:SEQ ID NO:13:

Asn Phe Gly Arg Leu His Ala Thr Thr Ala Val Ile Arg Asn Ile Asn  
 1 5 10 15  
 Asp Gln Val Leu Phe Val Asp Lys Arg Gln Pro Val Phe Glu Asp Met  
 20 25 30  
 Thr Asp Ile Asp Gln Ser Ala Ser Glu Pro Gln Thr Arg Leu Ile Ile  
 35 40 45  
 Tyr Met Tyr Lys Asp Ser Glu Val Arg Gly Leu Ala Val Thr Leu Ser  
 50 55 60  
 Val Lys Asp Ser Lys Met Ser Thr Leu Ser Cys Lys Asn Lys Ile Ile  
 65 70 75 80  
 Ser Phe Glu Glu Met Asp Pro Pro Glu Asn Ile Asp Asp Ile Gln Ser  
 85 90 95  
 Asp Leu Ile Phe Phe Gln Lys Arg Val Pro Gly His Asn Lys Met Glu  
 100 105 110  
 Phe Glu Ser Ser Leu Tyr Glu Gly His Phe Leu Ala Cys Gln Lys Glu  
 115 120 125  
 Asp Asp Ala Phe Lys Leu Ile Leu Lys Lys Lys Asp Glu Asn Gly Asp  
 130 135 140

Lys Ser Val Met Phe Thr Leu Thr Asn Leu His Gln Ser  
145 150 155

(15) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:157 amino acids

(B) TYPE:amino acid

(D) TOPOLOGY:linear

(ii) MOLECULE TYPE:peptide

(xi) SEQUENCE DESCRIPTION:SEQ ID NO:14:

Asn Phe Gly Arg Leu His Cys Thr Thr Ala Val Ile Arg Asn Ile Asn  
1 5 10 15  
Asp Gln Val Leu Phe Val Asp Lys Arg Gln Pro Val Phe Glu Asp Met  
20 25 30  
Thr Asp Ile Asp Gln Ser Ala Ser Glu Pro Gln Thr Arg Leu Ile Ile  
35 40 45  
Tyr Met Tyr Lys Asp Ser Glu Val Arg Gly Leu Ala Val Thr Leu Ser  
50 55 60  
Val Lys Asp Ser Lys Met Ser Thr Leu Ser Cys Lys Asn Lys Ile Ile  
65 70 75 80  
Ser Phe Glu Glu Met Asp Pro Pro Glu Asn Ile Asp Asp Ile Gln Ser  
85 90 95  
Asp Leu Ile Phe Phe Gln Lys Arg Val Pro Gly His Asn Lys Met Glu  
100 105 110  
Phe Glu Ser Ser Leu Tyr Glu Gly His Phe Leu Ala Ser Gln Lys Glu  
115 120 125  
Asp Asp Ala Phe Lys Leu Ile Leu Lys Lys Lys Asp Glu Asn Gly Asp  
130 135 140  
Lys Ser Val Met Phe Thr Leu Thr Asn Leu His Gln Ser  
145 150 155

(16) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:471 base pairs

(B) TYPE:nucleic acid

(C) STRANDEDNESS:double

(D) TOPOLOGY:linear

(ii) MOLECULE TYPE:cDNA

(ix) FEATURE:

(A) NAME/KEY:mat peptide

(B) LOCATION:1..471

(C) IDENTIFICATION METHODS:S

(xi) SEQUENCE DESCRIPTION:SEQ ID NO:15:

TAC TTT GGC AAG CTT GAA TCT AAA TTA TCA GTC ATA AGA AAT TTG AAT 48  
45 Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn 15  
1 5 10 15  
GAC CAA GTT CTC TTC ATT GAC CAA GGA AAT CGG CCT CTA TTT GAA GAT 96  
Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp 20 25 30  
20 25 30  
ATG ACT GAT TCT GAC TGT AGA GAT AAT GCA CCC CGG ACC ATA TTT ATT 144  
50 Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile 35 40 45  
35 40 45  
ATA AGT ATG TAT AAA GAT AGC CAG CCT AGA GGT ATG GCT GTA ACT ATC 192  
Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile 50 55 60  
50 55 60  
TCT GTG AAG TCT GAG AAA ATT TCA ACT CTC TCC TGT GAG AAC AAA ATT 240  
55 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile 55 60 65

65	ATT	TCC	TTT	AAG	GAA	ATG	AAT	CCT	CCT	GAT	AAC	ATC	AAG	GAT	ACA	AAA	288
	Ile	Ser	Phe	Lys	Glu	Met	Asn	Pro	Pro	Asp	Asn	Ile	Lys	Asp	Thr	Lys	
5	AGT	GAC	ATC	ATA	TTC	TTT	CAG	AGA	AGT	GTC	CCA	GGA	CAT	GAT	AAT	AAG	336
	Ser	Asp	Ile	Ile	Phe	Phe	Gln	Arg	Ser	Val	Pro	Gly	His	Asp	Asn	Lys	
10	ATG	CAA	TTT	GAA	TCT	TCA	TCA	TAC	GAA	GGA	TAC	TTT	CTA	GCT	TGT	GAA	384
	Met	Gln	Phe	Glu	Ser	Ser	Ser	Tyr	Glu	Gly	Tyr	Phe	Leu	Ala	Cys	Glu	
15	AAA	GAG	AGA	GAC	CTT	TTT	AAA	CTC	ATT	TTG	AAA	AAA	GAG	GAT	GAA	TTG	432
	Lys	Glu	Arg	Asp	Leu	Phe	Lys	Leu	Ile	Leu	Lys	Lys	Glu	Asp	Glu	Leu	
20	GGG	GAT	AGA	TCT	ATA	ATG	TTC	ACT	GTT	CAA	AAC	GAA	GAC				471
	Gly	Asp	Arg	Ser	Ile	Met	Phe	Thr	Val	Gln	Asn	Glu	Asp				

## (17) INFORMATION FOR SEQ ID NO:16:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 471 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

(A) NAME/KEY: mat peptide

(B) LOCATION: 1..471

(C) IDENTIFICATION METHODS: S

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

30	TAC	TTT	GGC	AAG	CTT	GAA	TCT	AAA	TTA	TCA	GTC	ATA	AGA	AAT	TTG	AAT	48
	Tyr	Phe	Gly	Lys	Leu	Glu	Ser	Lys	Leu	Ser	Val	Ile	Arg	Asn	Leu	Asn	
35	GAC	CAA	GTT	CTC	TTC	ATT	GAC	CAA	GGA	AAT	CGG	CCT	CTA	TTT	GAA	GAT	96
	Asp	Gln	Val	leu	Phe	Ile	Asp	Gln	Gly	Asn	Arg	Pro	Leu	Phe	Glu	Asp	
40	ATG	ACT	GAT	TCT	GAC	TCT	AGA	GAT	AAT	GCA	CCC	CGG	ACC	ATA	TTT	ATT	144
	Met	Thr	Asp	Ser	Asp	Ser	Arg	Asp	Asn	Ala	Pro	Arg	Thr	Ile	Phe	Ile	
45	ATA	AGT	ATG	TAT	AAA	GAT	AGC	CAG	CCT	AGA	GGT	ATG	GCT	GTA	ACT	ATC	192
	Ile	Ser	Met	Tyr	Lys	Asp	Ser	Gln	Pro	Arg	Gly	Met	Ala	Val	Thr	Ile	
50	TCT	GTG	AAG	TCT	GAG	AAA	ATT	TCA	ACT	CTC	TCC	TGT	GAG	AAC	AAA	ATT	240
	Ser	Val	Lys	Ser	Glu	Lys	Ile	Ser	Thr	Leu	Ser	Cys	Glu	Asn	Lys	Ile	
55	ATT	TCC	TTT	AAG	GAA	ATG	AAT	CCT	CCT	GAT	AAC	ATC	AAG	GAT	ACA	AAA	288
	Ile	Ser	Phe	Lys	Glu	Met	Asn	Pro	Pro	Asp	Asn	Ile	Lys	Asp	Thr	Lys	
60	AGT	GAC	ATC	ATA	TTC	TTT	CAG	AGA	AGT	GTC	CCA	GGA	CAT	GAT	AAT	AAG	336
	Ser	Asp	Ile	Ile	Phe	Phe	Gln	Arg	Ser	Val	Pro	Gly	His	Asp	Asn	Lys	
65	ATG	CAA	TTT	GAA	TCT	TCA	TCA	TAC	GAA	GGA	TAC	TTT	CTA	GCT	TGT	GAA	384
	Met	Gln	Phe	Glu	Ser	Ser	Ser	Tyr	Glu	Gly	Tyr	Phe	Leu	Ala	Cys	Glu	
70	AAA	GAG	AGA	GAC	CTT	TTT	AAA	CTC	ATT	TTG	AAA	AAA	GAG	GAT	GAA	TTG	432
	Lys	Glu	Arg	Asp	Leu	Phe	Lys	Leu	Ile	Leu	Lys	Lys	Glu	Asp	Glu	Leu	
75	GGG	GAT	AGA	TCT	ATA	ATG	TTC	ACT	GTT	CAA	AAC	GAA	GAC				471
	Gly	Asp	Arg	Ser	Ile	Met	Phe	Thr	Val	Gln	Asn	Glu	Asp				



## (18) INFORMATION FOR SEQ ID NO:17:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:471 base pairs

(B) TYPE:nucleic acid

(C) STRANDEDNESS:double

(D) TOPOLOGY:linear

(ii) MOLECULE TYPE:cDNA

## (ix) FEATURE:

(A) NAME/KEY:mat peptide

(B) LOCATION:1..471

(C) IDENTIFICATION METHODS:S

## (xi) SEQUENCE DESCRIPTION:SEQ ID NO:17:

```

15  TAC TTT GGC AAG CTT GAA TCT AAA TTA TCA GTC ATA AGA AAT TTG AAT      48
    Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn
    1           5           10           15
    GAC CAA GTT CTC TTC ATT GAC CAA GGA AAT CGG CCT CTA TTT GAA GAT      96
    Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp
    20           20           25           30
    ATG ACT GAT TCT GAC TGT AGA GAT AAT GCA CCC CGG ACC ATA TTT ATT      144
    Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile
    35           40           45
    ATA AGT ATG TAT AAA GAT AGC CAG CCT AGA GGT ATG GCT GTA ACT ATC      192
    Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile
    50           55           60
    TCT GTG AAG TCT GAG AAA ATT TCA ACT CTC TCC TGT GAG AAC AAA ATT      240
    Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile
    65           70           75           80
    ATT TCC TTT AAG GAA ATG AAT CCT CCT GAT AAC ATC AAG GAT ACA AAA      288
    Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys
    85           90           95
    AGT GAC ATC ATA TTC TTT CAG AGA AGT GTC CCA GGA CAT GAT AAT AAG      336
    Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys
    100          105          110
    ATG CAA TTT GAA TCT TCA TCA TAC GAA GGA TAC TTT CTA GCT TCT GAA      384
    Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Ser Glu
    115          120          125
    AAA GAG AGA GAC CTT TTT AAA CTC ATT TTG AAA AAA GAG GAT GAA TTG      432
    Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu
    130          135          140
    GGG GAT AGA TCT ATA ATG TTC ACT GTT CAA AAC GAA GAC      471
    Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp
    145          150          155

```

## (19) INFORMATION FOR SEQ ID NO:18:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:471 base pairs

(B) TYPE:nucleic acid

(C) STRANDEDNESS:double

(D) TOPOLOGY:linear

(ii) MOLECULE TYPE:cDNA

## (ix) FEATURE:

(A) NAME/KEY:mat peptide

(B) LOCATION:1..471

(C) IDENTIFICATION METHODS:S

## (xi) SEQUENCE DESCRIPTION:SEQ ID NO:18:

```

55  TAC TTT GGC AAG CTT GAA TCT AAA TTA TCA GTC ATA AGA AAT TTG AAT      48
    Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn

```

1	GAC	CAA	GTT	CTC	5	TTC	ATT	GAC	CAA	10	GGA	AAT	CGG	CCT	CTA	15	TTT	GAA	GAT	96
	Asp	Gln	Val	Leu		Phe	Ile	Asp	Gln		Gly	Asn	Arg	Pro	Leu		Phe	Glu	Asp	
5	ATG	ACT	GAT	TCT	20	GAC	TCT	AGA	GAT	25	AAT	GCA	CCC	CGG	ACC	30	ATA	TTT	ATT	144
	Met	Thr	Asp	Ser		Asp	Ser	Arg	Asp		Asn	Ala	Pro	Arg	Thr		Ile	Phe	Ile	
					35					40						45				
	ATA	AGT	ATG	TAT	50	AAA	GAT	AGC	CAG	55	CCT	AGA	GGT	ATG	GCT	60	GTA	ACT	ATC	192
	Ile	Ser	Met	Tyr		Lys	Asp	Ser	Gln		Pro	Arg	Gly	Met	Ala		Val	Thr	Ile	
10	TCT	GTG	AAG	TCT	65	GAG	AAA	ATT	TCA	70	ACT	CTC	TCC	TGT	GAG	75	AAC	AAA	ATT	240
	Ser	Val	Lys	Ser		Glu	Lys	Ile	Ser		Thr	Leu	Ser	Cys	Glu		Asn	Lys	Ile	
					85					90						95				
	ATT	TCC	TTT	AAG	100	GAA	ATG	AAT	CCT	105	CCT	GAT	AAC	ATC	AAG	110	GAT	ACA	AAA	288
	Ile	Ser	Phe	Lys		Glu	Met	Asn	Pro		Pro	Asp	Asn	Ile	Lys		Asp	Thr	Lys	
15	AGT	GAC	ATC	ATA	115	TTC	TTT	CAG	AGA	120	AGT	GTC	CCA	GGA	CAT	125	GAT	AAT	AAG	336
	Ser	Asp	Ile	Ile		Phe	Phe	Gln	Arg		Ser	Val	Pro	Gly	His		Asp	Asn	Lys	
					130					135						140				
	ATG	CAA	TTT	GAA	145	TCT	TCA	TCA	TAC	150	GAA	GGA	TAC	TTT	CTA	155	GCT	TCT	GAA	384
20	Met	Gln	Phe	Glu		Ser	Ser	Ser	Tyr		Glu	Gly	Tyr	Phe	Leu		Ala	Ser	Glu	
					165					170						175				
	AAA	GAG	AGA	GAC	180	CTT	TTT	AAA	CTC	185	ATT	TTG	AAA	AAA	GAG	190	GAT	GAA	TTG	432
	Lys	Glu	Arg	Asp		Leu	Phe	Lys	Leu		Ile	Leu	Lys	Lys	Glu		Asp	Glu	Leu	
					200					205						210				
	GGG	GAT	AGA	TCT	215	ATA	ATG	TTC	ACT	220	GTT	CAA	AAC	GAA	GAC	225				471
25	Gly	Asp	Arg	Ser		Ile	Met	Phe	Thr		Val	Gln	Asn	Glu	Asp					
					230					235						240				

## (20) INFORMATION FOR SEQ ID NO:19:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 471 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

(A) NAME/KEY: mat peptide

(B) LOCATION: 1..471

(C) IDENTIFICATION METHODS: S

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

40	TAC	TTT	GGC	AAG	CTT	GAA	TCT	AAA	TTA	TCA	GTC	ATA	AGA	AAT	TTG	AAT	48			
	Tyr	Phe	Gly	Lys	Leu	Glu	Ser	Lys	Leu	Ser	Val	Ile	Arg	Asn	Leu	Asn				
					5					10										
	GAC	CAA	GTT	CTC	20	TTC	ATT	GAC	CAA	25	GGA	AAT	CGG	CCT	CTA	30	TTT	GAA	GAT	96
45	Asp	Gln	Val	Leu		Phe	Ile	Asp	Gln		Gly	Asn	Arg	Pro	Leu		Phe	Glu	Asp	
					35					40						45				
	ATA	AGT	ATG	TAT	50	AAA	GAT	AGC	CAG	55	CCT	AGA	GGT	ATG	GCT	60	GTA	ACT	ATC	192
	Ile	Ser	Met	Tyr		Lys	Asp	Ser	Gln		Pro	Arg	Gly	Met	Ala		Val	Thr	Ile	
50	TCT	GTG	AAG	TCT	65	GAG	AAA	ATT	TCA	70	ACT	CTC	TCC	TCT	GAG	75	AAC	AAA	ATT	240
	Ser	Val	Lys	Ser		Glu	Lys	Ile	Ser		Thr	Leu	Ser	Ser	Glu		Asn	Lys	Ile	
					85					90						95				
	ATT	TCC	TTT	AAG	100	GAA	ATG	AAT	CCT	105	CCT	GAT	AAC	ATC	AAG	110	GAT	ACA	AAA	288
55	Ile	Ser	Phe	Lys		Glu	Met	Asn	Pro		Pro	Asp	Asn	Ile	Lys		Asp	Thr	Lys	
					115					120						125				

AGT GAC ATC ATA TTC TTT CAG AGA AGT GTC CCA GGA CAT GAT AAT AAG 336  
 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys  
 100 105 110  
 5 ATG CAA TTT GAA TCT TCA TCA TAC GAA GGA TAC TTT CTA GCT TCT GAA 384  
 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Ser Glu  
 115 120 125  
 AAA GAG AGA GAC CTT TTT AAA CTC ATT TTG AAA AAA GAG GAT GAA TTG 432  
 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu  
 130 135 140  
 10 GGG GAT AGA TCT ATA ATG TTC ACT GTT CAA AAC GAA GAC 471  
 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp  
 145 150 155

(21) INFORMATION FOR SEQ ID NO:20:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 471 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: cDNA  
 (ix) FEATURE:  
 (A) NAME/KEY: mat peptide  
 (B) LOCATION: 1..471  
 (C) IDENTIFICATION METHODS: S  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

TAC TTT GGC AAG CTT GAA TCT AAA TTA TCA GTC ATA AGA AAT TTG AAT 48  
 Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn  
 1 5 10 15  
 GAC CAA GTT CTC TTC ATT GAC CAA GGA AAT CGG CCT CTA TTT GAA GAT 96  
 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp  
 20 25 30  
 ATG ACT GAT TCT GAC TCT AGA GAT AAT GCA CCC CGG ACC ATA TTT ATT 144  
 Met Thr Asp Ser Asp Ser Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile  
 35 40 45  
 ATA AGT ATG TAT AAA GAT AGC CAG CCT AGA GGT ATG GCT GTA ACT ATC 192  
 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile  
 50 55 60  
 TCT GTG AAG TCT GAG AAA ATT TCA ACT CTC TCC GCT GAG AAC AAA ATT 240  
 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Ala Glu Asn Lys Ile  
 65 70 75 80  
 ATT TCC TTT AAG GAA ATG AAT CCT CCT GAT AAC ATC AAG GAT ACA AAA 288  
 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys  
 85 90 95  
 AGT GAC ATC ATA TTC TTT CAG AGA AGT GTC CCA GGA CAT GAT AAT AAG 336  
 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys  
 100 105 110  
 45 ATG CAA TTT GAA TCT TCA TCA TAC GAA GGA TAC TTT CTA GCT TGT GAA 384  
 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu  
 115 120 125  
 AAA GAG AGA GAC CTT TTT AAA CTC ATT TTG AAA AAA GAG GAT GAA TTG 432  
 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu  
 130 135 140  
 50 GGG GAT AGA TCT ATA ATG TTC ACT GTT CAA AAC GAA GAC 471  
 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp  
 145 150 155

(22) INFORMATION FOR SEQ ID NO:21:  
 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:471 base pairs  
 (B) TYPE:nucleic acid  
 (C) STRANDEDNESS:double  
 (D) TOPOLOGY:linear

(ii) MOLECULE TYPE:cdna

(ix) FEATURE:

(A) NAME/KEY:mat peptide

(B) LOCATION:1..471

(C) IDENTIFICATION METHODS:S

(xi) SEQUENCE DESCRIPTION:SEQ ID NO:21:

```

TAC TTT GGC AAG CTT GAA TCT AAA TTA TCA GTC ATA AGA AAT TTG AAT      48
Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn
1      5      10      15
GAC CAA GTT CTC TTC ATT GAC CAA GGA AAT CGG CCT CTA TTT GAA GAT      96
Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp
20      25      30
ATG ACT GAT TCT GAC TCT AGA GAT AAT GCA CCC CGG ACC ATA TTT ATT      144
Met Thr Asp Ser Asp Ser Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile
35      40      45
ATA AGT ATG TAT AAA GAT AGC CAG CCT AGA GGT ATG GCT GTA ACT ATC      192
Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile
50      55      60
TCT GTG AAG TCT GAG AAA ATT TCA ACT CTC TCC GCT GAG AAC AAA ATT      240
Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Ala Glu Asn Lys Ile
65      70      75      80
ATT TCC TTT AAG GAA ATG AAT CCT CCT GAT AAC ATC AAG GAT ACA AAA      288
Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys
85      90      95
AGT GAC ATC ATA TTC TTT CAG AGA AGT GTC CCA GGA CAT GAT AAT AAG      336
Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys
100      105      110
ATG CAA TTT GAA TCT TCA TCA TAC GAA GGA TAC TTT CTA GCT TCT GAA      384
Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Ser Glu
115      120      125
AAA GAG AGA GAC CTT TTT AAA CTC ATT TTG AAA AAA GAG GAT GAA TTG      432
Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu
130      135      140
GGG GAT AGA TCT ATA ATG TTC ACT GTT CAA AAC GAA GAC      471
Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp
145      150      155

```

(23) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:471 base pairs

(B) TYPE:nucleic acid

(C) STRANDEDNESS:double

(D) TOPOLOGY:linear

(ii) MOLECULE TYPE:cdna

(ix) FEATURE:

(A) NAME/KEY:mat peptide

(B) LOCATION:1..471

(C) IDENTIFICATION METHODS:S

(xi) SEQUENCE DESCRIPTION:SEQ ID NO:22:

```

AAC TTT GGC CGA CTT CAC GCT ACA ACC GCA GTA ATA CGG AAT ATA AAT      48
Asn Phe Gly Arg Leu His Ala Thr Thr Ala Val Ile Arg Asn Ile Asn
1      5      10      15
GAC CAA GTT CTC TTC GTT GAC AAA AGA CAG CCT GTG TTC GAG GAT ATG      96
Asp Gln Val Leu Phe Val Asp Lys Arg Gln Pro Val Phe Glu Asp Met
20      25      30

```

25

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

55

TTT GAA TCT TCA CTG TAT GAA GGA CAC TTT CTT GCT AGC CAA AAG GAA 384  
Phe Glu Ser Ser Leu Tyr Glu Gly His Phe Leu Ala Ser Gln Lys Glu  
115 120 125  
5 GAT GAT GCT TTC AAA CTC ATT CTG AAA AAA AAG GAT GAA AAT GGG GAT 432  
Asp Asp Ala Phe Lys Leu Ile Leu Lys Lys Lys Asp Glu Asn Gly Asp  
130 135 140  
AAA TCT GTA ATG TTC ACT CTC ACT AAC TTA CAT CAA AGT 471  
Lys Ser Val Met Phe Thr Leu Thr Asn Leu His Gln Ser  
145 150 155

## (25) INFORMATION FOR SEQ ID NO:24:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 69 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: Other nucleic acid

## (ix) FEATURE:

(A) NAME/KEY: sig peptide

(B) LOCATION: 1..69

(C) IDENTIFICATION METHODS: S

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

ATGGCCTTGA CCTTTGCTTT ACTGGTGGCC CTCCTGGTGC TCAGCTGCAA GTCAAGCTGC 60  
TCTGTGGGC 69

## (26) INFORMATION FOR SEQ ID NO:25:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 471 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(F) TISSUE TYPE: liver

## (ix) FEATURE:

(A) NAME/KEY: mat peptide

(B) LOCATION: 1..471

(C) IDENTIFICATION METHODS: E

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

TAC TTT GGC AAG CTT GAA TCT AAA TTA TCA GTC ATA AGA AAT TTG AAT 48  
Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn  
1 5 10 15  
GAC CAA GTT CTC TTC ATT GAC CAA GGA AAT CGG CCT CTA TTT GAA GAT 96  
Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp  
20 25 30  
ATG ACT GAT TCT GAC TGT AGA GAT AAT GCA CCC CGG ACC ATA TTT ATT 144  
Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile  
35 40 45  
ATA AGT ATG TAT AAA GAT AGC CAG CCT AGA GGT ATG GCT GTA ACT ATC 192  
Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile  
50 55 60  
TCT GTG AAG TGT GAG AAA ATT TCA ACT CTC TCC TGT GAG AAC AAA ATT 240  
Ser Val Lys Cys Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile  
65 70 75 80  
ATT TCC TTT AAG GAA ATG AAT CCT CCT GAT AAC ATC AAG GAT ACA AAA 288  
Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys

```

      85          90          95
AGT GAC ATC ATA TTC TTT CAG AGA AGT GTC CCA GGA CAT GAT AAT AAG 336
Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys
      100      105      110
5  ATG CAA TTT GAA TCT TCA TCA TAC GAA GGA TAC TTT CTA GCT TGT GAA 384
Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu
      115      120      125
AAA GAG AGA GAC CTT TTT AAA CTC ATT TTG AAA AAA GAG GAT GAA TTG 432
Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu
      130      135      140
10 GGG GAT AGA TCT ATA ATG TTC ACT GTT CAA AAC GAA GAC 471
Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp
      145      150      155

```

```

15 (27) INFORMATION FOR SEQ ID NO:26:
    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH:570 base pairs
        (B) TYPE:nucleic acid
        (C) STRANDEDNESS:double
        (D) TOPOLOGY:linear
20    (ii) MOLECULE TYPE:cDNA
    (ix) FEATURE:
        (A) NAME/KEY:5' UTR
        (B) LOCATION:1..15
        (C) IDENTIFICATION METHODS:S
25        (A) NAME/KEY:sig peptide
        (B) LOCATION:16..84
        (C) IDENTIFICATION METHODS:S
        (A) NAME/KEY:mat peptide
        (B) LOCATION:85..555
30        (C) IDENTIFICATION METHODS:S
        (A) NAME/KEY:3' UTR
        (B) LOCATION:556..570
        (C) IDENTIFICATION METHODS:S
    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

```

```

35 ACACCTCGAG CCACC ATG GCC TTG ACC TTT GCT TTA CTG GTG GCC CTC CTG 51
    Met Ala Leu Thr Phe Ala Leu Leu Val Ala Leu Leu
      -20      -15
GTG CTC AGC TGC AAG TCA AGC TGC TCT GTG GGC TAC TTT GGC AAG CTT 99
Val Leu Ser Cys Lys Ser Ser Cys Ser Val Gly Tyr Phe Gly Lys Leu
      -10      -5      1      5
40 GAA TCT AAA TTA TCA GTC ATA AGA AAT TTG AAT GAC CAA GTT CTC TTC 147
Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn Asp Gln Val Leu Phe
      10      15      20
ATT GAC CAA GGA AAT CGG CCT CTA TTT GAA GAT ATG ACT GAT TCT GAC 195
Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp Met Thr Asp Ser Asp
      25      30      35
45 TGT AGA GAT AAT GCA CCC CGG ACC ATA TTT ATT ATA AGT ATG TAT AAA 243
Cys Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile Ile Ser Met Tyr Lys
      40      45      50
GAT AGC CAG CCT AGA GGT ATG GCT GTA ACT ATC TCT GTG AAG TGT GAG 291
Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile Ser Val Lys Cys Glu
      55      60      65
50 AAA ATT TCA ACT CTC TCC TGT GAG AAC AAA ATT ATT TCC TTT AAG GAA 339
Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile Ile Ser Phe Lys Glu
      70      75      80      85
ATG AAT CCT CCT GAT AAC ATC AAG GAT ACA AAA AGT GAC ATC ATA TTC 387
Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys Ser Asp Ile Ile Phe
      90      95      100

```



TTT CAG AGA AGT GTC CCA GGA CAT GAT AAT AAG ATG CAA TTT GAA TCT 435  
Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys Met Gln Phe Glu Ser  
105 110 115  
5 TCA TCA TAC GAA GGA TAC TTT CTA GCT TGT GAA AAA GAG AGA GAC CTT 483  
Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu Lys Glu Arg Asp Leu  
120 125 130  
TTT AAA CTC ATT TTG AAA AAA GAG GAT GAA TTG GGG GAT AGA TCT ATA 531  
Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu Gly Asp Arg Ser Ile  
135 140 145  
10 ATG TTC ACT GTT CAA AAC GAA GAC TAGGCGGCCG CGTGT 570  
Met Phe Thr Val Gln Asn Glu Asp  
150 155

(28) INFORMATION FOR SEQ ID NO:27:  
15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH:10 amino acids  
(B) TYPE:amino acid  
(D) TOPOLOGY:linear  
(ii) MOLECULE TYPE:peptide  
20 (v) FRAGMENT TYPE:N-terminal fragment  
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:27:

Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser  
1 5 10

25 (29) INFORMATION FOR SEQ ID NO:28:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH:471 base pairs  
30 (B) TYPE:nucleic acid  
(C) STRANDEDNESS:double  
(D) TOPOLOGY:linear  
(ii) MOLECULE TYPE:cdna  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM:mouse  
(F) TISSUE TYPE:liver  
35 (ix) FEATURE:  
(A) NAME/KEY:mat peptide  
(B) LOCATION:1..471  
(C) IDENTIFICATION METHODS:E  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

40 AAC TTT GGC CGA CTT CAC TGT ACA ACC GCA GTA ATA CGG AAT ATA AAT 48  
Asn Phe Gly Arg Leu His Cys Thr Thr Ala Val Ile Arg Asn Ile Asn  
1 5 10 15  
GAC CAA GTT CTC TTC GTT GAC AAA AGA CAG CCT GTG TTC GAG GAT ATG 96  
Asp Gln Val Leu Phe Val Asp Lys Arg Gln Pro Val Phe Glu Asp Met  
20 25 30  
45 ACT GAT ATT GAT CAA AGT GCC AGT GAA CCC CAG ACC AGA CTG ATA ATA 144  
Thr Asp Ile Asp Gln Ser Ala Ser Glu Pro Gln Thr Arg Leu Ile Ile  
35 40 45  
TAC ATG TAC AAA GAC AGT GAA GTA AGA GGA CTG GCT GTG ACC CTC TCT 192  
Tyr Met Tyr Lys Asp Ser Glu Val Arg Gly Leu Ala Val Thr Leu Ser  
50 55 60  
GTG AAG GAT AGT AAA ATG TCT ACC CTC TCC TGT AAG AAC AAG ATC ATT 240  
Val Lys Asp Ser Lys Met Ser Thr Leu Ser Cys Lys Asn Lys Ile Ile  
65 70 75 80  
55 TCC TTT GAG GAA ATG GAT CCA CCT GAA AAT ATT GAT GAT ATA CAA AGT 288  
Ser Phe Glu Glu Met Asp Pro Pro Glu Asn Ile Asp Asp Ile Gln Ser  
85 90 95

**EP 0 845 530 A2**

GAT	CTC	ATA	TTC	TTT	CAG	AAA	CGT	GTT	CCA	GGA	CAC	AAC	AAG	ATG	GAG	336
Asp	Leu	Ile	Phe	Phe	Gln	Lys	Arg	Val	Pro	Gly	His	Asn	Lys	Met	Glu	
			100					105					110			
TTT	GAA	TCT	TCA	CTG	TAT	GAA	GGA	CAC	TTT	CTT	GCT	TGC	CAA	AAG	GAA	384
Phe	Glu	Ser	Ser	Leu	Tyr	Glu	Gly	His	Phe	Leu	Ala	Cys	Gln	Lys	Glu	
			115				120					125				
GAT	GAT	GCT	TTC	AAA	CTC	ATT	CTG	AAA	AAA	AAG	GAT	GAA	AAT	GGG	GAT	432
Asp	Asp	Ala	Phe	Lys	Leu	Ile	Leu	Lys	Lys	Lys	Asp	Glu	Asn	Gly	Asp	
			130			135					140					
AAA	TCT	GTA	ATG	TTC	ACT	CTC	ACT	AAC	TTA	CAT	CAA	AGT				471
Lys	Ser	Val	Met	Phe	Thr	Leu	Thr	Asn	Leu	His	Gln	Ser				
145					150					155						

```
(30) INFORMATION FOR SEQ ID NO:29:
      (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH:570 base pairs
            (B) TYPE:nucleic acid
            (C) STRANDEDNESS:double
            (D) TOPOLOGY:linear
      (ii) MOLECULE TYPE:cDNA
      (ix) FEATURE:
            (A) NAME/KEY:5' UTR
            (B) LOCATION:1..15
            (C) IDENTIFICATION METHODS:S
            (A) NAME/KEY:sig peptide
            (B) LOCATION:16..84
            (C) IDENTIFICATION METHODS:S
            (A) NAME/KEY:mat peptide
            (B) LOCATION:85..555
            (C) IDENTIFICATION METHODS:S
            (A) NAME/KEY:3' UTR
            (B) LOCATION:556..570
            (C) IDENTIFICATION METHODS:S
      (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:
```

ACACCTCGAG	CCACC	ATG	GCC	TTG	ACC	TTT	GCT	TTA	CTG	GTG	GCC	CTC	CTG	51		
		Met	Ala	Leu	Thr	Phe	Ala	Leu	Leu	Val	Ala	Leu	Leu			
					-20					-15						
GTG	CTC	AGC	TGC	AAG	TCA	AGC	TGC	TCT	GTG	GGC	AAC	TTT	GGC	CGA	CTT	99
Val	Leu	Ser	Cys	Lys	Ser	Ser	Cys	Ser	Val	Gly	Asn	Phe	Gly	Arg	Leu	
	-10					-5					1				5	
CAC	TGT	ACA	ACC	GCA	GTA	ATA	CGG	AAT	ATA	AAT	GAC	CAA	GTT	CTC	TTC	147
His	Cys	Thr	Thr	Ala	Val	Ile	Arg	Asn	Ile	Asn	Asp	Gln	Val	Leu	Phe	
			10					15						20		
GTT	GAC	AAA	AGA	CAG	CCT	GTG	TTC	GAG	GAT	ATG	ACT	GAT	ATT	GAT	CAA	195
Val	Asp	Lys	Arg	Gln	Pro	Val	Phe	Glu	Asp	Met	Thr	Asp	Ile	Asp	Gln	
			25					30				35				
AGT	GCC	AGT	GAA	CCC	CAG	ACC	AGA	CTG	ATA	ATA	TAC	ATG	TAC	AAA	GAC	243
Ser	Ala	Ser	Glu	Pro	Gln	Thr	Arg	Leu	Ile	Ile	Tyr	Met	Tyr	Lys	Asp	
		40					45					50				
AGT	GAA	GTA	AGA	GGA	CTG	GCT	GTG	ACC	CTC	TCT	GTG	AAG	GAT	AGT	AAA	291
Ser	Glu	Val	Arg	Gly	Leu	Ala	Val	Thr	Leu	Ser	Val	Lys	Asp	Ser	Lys	
	55				60						65					
ATG	TCT	ACC	CTC	TCC	TGT	AAG	AAC	AAG	ATC	ATT	TCC	TTT	GAG	GAA	ATG	339
Met	Ser	Thr	Leu	Ser	Cys	Lys	Asn	Lys	Ile	Ile	Ser	Phe	Glu	Glu	Met	
70					75				80						85	
GAT	CCA	CCT	GAA	AAT	ATT	GAT	GAT	ATA	CAA	AGT	GAT	CTC	ATA	TTC	TTT	387
Asp	Pro	Pro	Glu	Asn	Ile	Asp	Asp	Ile	Gln	Ser	Asp	Leu	Ile	Phe	Phe	
			90						95					100		
CAG	AAA	CGT	GTT	CCA	GGA	CAC	AAC	AAG	ATG	GAG	TTT	GAA	TCT	TCA	CTG	435

Gln Lys Arg Val Pro Gly His Asn Lys Met Glu Phe Glu Ser Ser Leu  
 105 110 115  
 TAT GAA GGA CAC TTT CTT GCT TGC CAA AAG GAA GAT GAT GCT TTC AAA 483  
 5 Tyr Glu Gly His Phe Leu Ala Cys Gln Lys Glu Asp Asp Ala Phe Lys  
 120 125 130  
 CTC ATT CTG AAA AAA AAG GAT GAA AAT GGG GAT AAA TCT GTA ATG TTC 531  
 Leu Ile Leu Lys Lys Lys Asp Glu Asn Gly Asp Lys Ser Val Met Phe  
 135 140 145  
 ACT CTC ACT AAC TTA CAT CAA AGT TAGGCGGCCG CGTGT 570  
 10 Thr Leu Thr Asn Leu His Gln Ser  
 150 155

## (31) INFORMATION FOR SEQ ID NO:30:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: N-terminal fragment

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Asn Phe Gly Arg Leu His  
 1 5

## Claims

1. An isolated polypeptide which is capable of inducing the production of interferon-gamma by immunocompetent cells, said polypeptide containing either amino acid sequence wherein one or more cysteines are replaced with different amino acid(s) while leaving respective consensus sequences as shown in SEQ ID NOs: 1-3 intact, or that wherein one or more amino acids are added, removed and/or replaced at one or more sites including those in the consensus sequences but excluding those of the replaced cysteine(s);

## SEQ ID NO: 1:

Asn Asp Gln Val Leu Phe  
 1 5

## SEQ ID NO: 2:

Phe Glu Asp Met Thr Asp  
 1 5

## SEQ ID NO: 3:

Met Tyr Lys Asp Ser.  
 1 5

2. The polypeptide of claim 1, wherein said different amino acid(s) is one or more amino acids selected from the group consisting of serine, threonine, alanine, valine, leucine, isoleucine, histidine, tyrosine, phenylalanine, tryptophan, and methionine.
3. The polypeptide of claim 1, wherein the amino acid sequence wherein one or more cysteines are replaced with different amino acid(s) is derived from the amino acid sequence of SEQ ID NO: 4, containing SEQ ID NOs: 1-3 as consensus sequences;

## SEQ ID NO: 4:

5 Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn  
 1 5 10 15  
 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp  
 20 25 30  
 Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile  
 10 35 40 45  
 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile  
 50 55 60  
 Ser Val Lys Cys Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile  
 65 70 75 80  
 15 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys  
 85 90 95  
 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys  
 100 105 110  
 20 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu  
 115 120 125  
 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu  
 130 135 140  
 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp.  
 145 150 155  
 25

4. The polypeptide of claim 1, wherein the amino acid sequence wherein one or more cysteines replaced with different amino acid(s) is derived from the amino acid sequence of SEQ ID NO:5, containing SEQ ID NOs:1-3 as consensus sequences;

## SEQ ID NO: 5:

35 Asn Phe Gly Arg Leu His Cys Thr Thr Ala Val Ile Arg Asn Ile Asn  
 1 5 10 15  
 Asp Gln Val Leu Phe Val Asp Lys Arg Gln Pro Val Phe Glu Asp Met  
 20 25 30  
 Thr Asp Ile Asp Gln Ser Ala Ser Glu Pro Gln Thr Arg Leu Ile Ile  
 35 40 45  
 40 Tyr Met Tyr Lys Asp Ser Glu Val Arg Gly Leu Ala Val Thr Leu Ser  
 50 55 60  
 Val Lys Asp Ser Lys Met Ser Thr Leu Ser Cys Lys Asn Lys Ile Ile  
 65 70 75 80  
 Ser Phe Glu Glu Met Asp Pro Pro Glu Asn Ile Asp Asp Ile Gln Ser  
 85 90 95  
 45 Asp Leu Ile Phe Phe Gln Lys Arg Val Pro Gly His Asn Lys Met Glu  
 100 105 110  
 Phe Glu Ser Ser Leu Tyr Glu Gly His Phe Leu Ala Cys Gln Lys Glu  
 115 120 125  
 50 Asp Asp Ala Phe Lys Leu Ile Leu Lys Lys Lys Asp Glu Asn Gly Asp  
 130 135 140  
 Lys Ser Val Met Phe Thr Leu Thr Asn Leu His Gln Ser.  
 145 150 155

- 55 5. The polypeptide of claim 1, which contains an amino acid sequence selected from the group consisting of SEQ ID NOs:6-12, derived from the amino acid sequence of SEQ ID NO:4;

## SEQ ID NO: 6:

Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn  
 1 5 10 15  
 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp  
 20 25 30  
 Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile  
 35 40 45  
 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile  
 50 55 60  
 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile  
 65 70 75 80  
 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys  
 85 90 95  
 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys  
 100 105 110  
 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu  
 115 120 125  
 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu  
 130 135 140  
 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp  
 145 150 155

## 25 SEQ ID NO: 7:

Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn  
 1 5 10 15  
 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp  
 20 25 30  
 Met Thr Asp Ser Asp Ser Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile  
 35 40 45  
 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile  
 50 55 60  
 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile  
 65 70 75 80  
 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys  
 85 90 95  
 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys  
 100 105 110  
 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu  
 115 120 125  
 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu  
 130 135 140  
 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp  
 145 150 155

## SEQ ID NO: 8:

Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn  
 1 5 10 15  
 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp  
 20 25 30  
 Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile  
 55

35 40 45  
 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile  
 50 55 60  
 5 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile  
 65 70 75 80  
 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys  
 85 90 95  
 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys  
 100 105 110  
 10 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Ser Glu  
 115 120 125  
 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu  
 130 135 140  
 15 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp  
 145 150 155

SEQ ID NO: 9:

Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn  
 1 5 10 15  
 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp  
 20 25 30  
 Met Thr Asp Ser Asp Ser Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile  
 35 40 45  
 25 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile  
 50 55 60  
 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile  
 65 70 75 80  
 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys  
 85 90 95  
 30 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys  
 100 105 110  
 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Ser Glu  
 115 120 125  
 35 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu  
 130 135 140  
 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp  
 145 150 155

SEQ ID NO: 10:

Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn  
 1 5 10 15  
 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp  
 20 25 30  
 45 Met Thr Asp Ser Asp Ser Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile  
 35 40 45  
 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile  
 50 55 60  
 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile  
 65 70 75 80  
 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys  
 85 90 95  
 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys  
 100 105 110  
 55 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Ser Glu  
 115 120 125

Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu  
 130 135 140  
 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp  
 145 150 155

SEQ ID NO: 11:

Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn  
 1 5 10 15  
 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp  
 20 25 30  
 Met Thr Asp Ser Asp Ser Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile  
 35 40 45  
 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile  
 50 55 60  
 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Ala Glu Asn Lys Ile  
 65 70 75 80  
 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys  
 85 90 95  
 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys  
 100 105 110  
 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu  
 115 120 125  
 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu  
 130 135 140  
 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp  
 145 150 155

SEQ ID NO: 12:

Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn  
 1 5 10 15  
 Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp  
 20 25 30  
 Met Thr Asp Ser Asp Ser Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile  
 35 40 45  
 Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile  
 50 55 60  
 Ser Val Lys Ser Glu Lys Ile Ser Thr Leu Ser Ala Glu Asn Lys Ile  
 65 70 75 80  
 Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys  
 85 90 95  
 Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys  
 100 105 110  
 Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Ser Glu  
 115 120 125  
 Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu  
 130 135 140  
 Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp.  
 145 150 155

6. The polypeptide of claim 1, which contains an amino acid sequence selected from the group consisting of SEQ ID NOs:13 and 14, derived from the amino acid sequence of SEQ ID NO:5;

## SEQ ID NO: 13:

5 Asn Phe Gly Arg Leu His Ala Thr Thr Ala Val Ile Arg Asn Ile Asn  
 1 5 10 15  
 Asp Gln Val Leu Phe Val Asp Lys Arg Gln Pro Val Phe Glu Asp Met  
 20 25 30  
 Thr Asp Ile Asp Gln Ser Ala Ser Glu Pro Gln Thr Arg Leu Ile Ile  
 35 40 45  
 10 Tyr Met Tyr Lys Asp Ser Glu Val Arg Gly Leu Ala Val Thr Leu Ser  
 50 55 60  
 Val Lys Asp Ser Lys Met Ser Thr Leu Ser Cys Lys Asn Lys Ile Ile  
 65 70 75 80  
 15 Ser Phe Glu Glu Met Asp Pro Pro Glu Asn Ile Asp Asp Ile Gln Ser  
 85 90 95  
 Asp Leu Ile Phe Phe Gln Lys Arg Val Pro Gly His Asn Lys Met Glu  
 100 105 110  
 Phe Glu Ser Ser Leu Tyr Glu Gly His Phe Leu Ala Cys Gln Lys Glu  
 115 120 125  
 20 Asp Asp Ala Phe Lys Leu Ile Leu Lys Lys Lys Asp Glu Asn Gly Asp  
 130 135 140  
 Lys Ser Val Met Phe Thr Leu Thr Asn Leu His Gln Ser  
 145 150 155

## SEQ ID NO: 14:

25 Asn Phe Gly Arg Leu His Cys Thr Thr Ala Val Ile Arg Asn Ile Asn  
 1 5 10 15  
 30 Asp Gln Val Leu Phe Val Asp Lys Arg Gln Pro Val Phe Glu Asp Met  
 20 25 30  
 Thr Asp Ile Asp Gln Ser Ala Ser Glu Pro Gln Thr Arg Leu Ile Ile  
 35 40 45  
 Tyr Met Tyr Lys Asp Ser Glu Val Arg Gly Leu Ala Val Thr Leu Ser  
 50 55 60  
 35 Val Lys Asp Ser Lys Met Ser Thr Leu Ser Cys Lys Asn Lys Ile Ile  
 65 70 75 80  
 Ser Phe Glu Glu Met Asp Pro Pro Glu Asn Ile Asp Asp Ile Gln Ser  
 85 90 95  
 40 Asp Leu Ile Phe Phe Gln Lys Arg Val Pro Gly His Asn Lys Met Glu  
 100 105 110  
 Phe Glu Ser Ser Leu Tyr Glu Gly His Phe Leu Ala Ser Gln Lys Glu  
 115 120 125  
 Asp Asp Ala Phe Lys Leu Ile Leu Lys Lys Lys Asp Glu Asn Gly Asp  
 130 135 140  
 45 Lys Ser Val Met Phe Thr Leu Thr Asn Leu His Gln Ser.  
 145 150 155

50 7. The polypeptide of claims 1, which additionally has one or more properties selected from the group consisting of enhancing cytotoxicities of killer cells and inducing formation of killer cells.

8. The polypeptide of claim 3, which additionally has one or more properties selected from the group consisting of enhancing cytotoxicity of killer cells and inducing formation of killer cells.

55 9. A DNA encoding the polypeptide of claim 1.

10. The DNA of claim 9, which contains a nucleotide sequence selected either from the group consisting of the nucleotide sequences of SEQ ID NOs:15-23 and their complementary nucleotide sequences, or from the other group



EP 0 845 530 A2

consisting of the nucleotide sequences derived from one of the nucleotide sequences of the former group by replacing one or more of the nucleotides with different one(s) without altering the amino acid sequences encoded thereby;

5

SEQ ID NO: 15:

	TAC	TTT	GGC	AAG	CTT	GAA	TCT	AAA	TTA	TCA	GTC	ATA	AGA	AAT	TTG	AAT	48
	Tyr	Phe	Gly	Lys	Leu	Glu	Ser	Lys	Leu	Ser	Val	Ile	Arg	Asn	Leu	Asn	
10	1				5				10						15		
	GAC	CAA	GTT	CTC	TTC	ATT	GAC	CAA	GGA	AAT	CGG	CCT	CTA	TTT	GAA	GAT	96
	Asp	Gln	Val	Leu	Phe	Ile	Asp	Gln	Gly	Asn	Arg	Pro	Leu	Phe	Glu	Asp	
				20					25					30			
	ATG	ACT	GAT	TCT	GAC	TGT	AGA	GAT	AAT	GCA	CCC	CGG	ACC	ATA	TTT	ATT	144
15	Met	Thr	Asp	Ser	Asp	Cys	Arg	Asp	Asn	Ala	Pro	Arg	Thr	Ile	Phe	Ile	
			35					40					45				
	ATA	AGT	ATG	TAT	AAA	GAT	AGC	CAG	CCT	AGA	GGT	ATG	GCT	GTA	ACT	ATC	192
	Ile	Ser	Met	Tyr	Lys	Asp	Ser	Gln	Pro	Arg	Gly	Met	Ala	Val	Thr	Ile	
			50					55					60				
	TCT	GTG	AAG	TCT	GAG	AAA	ATT	TCA	ACT	CTC	TCC	TGT	GAG	AAC	AAA	ATT	240
20	Ser	Val	Lys	Ser	Glu	Lys	Ile	Ser	Thr	Leu	Ser	Cys	Glu	Asn	Lys	Ile	
	65					70					75				80		
	ATT	TCC	TTT	AAG	GAA	ATG	AAT	CCT	CCT	GAT	AAC	ATC	AAG	GAT	ACA	AAA	288
	Ile	Ser	Phe	Lys	Glu	Met	Asn	Pro	Pro	Asp	Asn	Ile	Lys	Asp	Thr	Lys	
				85						90				95			
25	AGT	GAC	ATC	ATA	TTC	TTT	CAG	AGA	AGT	GTC	CCA	GGA	CAT	GAT	AAT	AAG	336
	Ser	Asp	Ile	Ile	Phe	Phe	Gln	Arg	Ser	Val	Pro	Gly	His	Asp	Asn	Lys	
				100					105				110				
	ATG	CAA	TTT	GAA	TCT	TCA	TCA	TAC	GAA	GGA	TAC	TTT	CTA	GCT	TGT	GAA	384
	Met	Gln	Phe	Glu	Ser	Ser	Ser	Tyr	Glu	Gly	Tyr	Phe	Leu	Ala	Cys	Glu	
			115					120					125				
30	AAA	GAG	AGA	GAC	CTT	TTT	AAA	CTC	ATT	TTG	AAA	AAA	GAG	GAT	GAA	TTG	432
	Lys	Glu	Arg	Asp	Leu	Phe	Lys	Leu	Ile	Leu	Lys	Lys	Glu	Asp	Glu	Leu	
			130				135					140					
	GGG	GAT	AGA	TCT	ATA	ATG	TTC	ACT	GTT	CAA	AAC	GAA	GAC				471
35	Gly	Asp	Arg	Ser	Ile	Met	Phe	Thr	Val	Gln	Asn	Glu	Asp				
	145					150					155						

40

45

50

55

## SEQ ID NO: 16:

5	TAC	TTT	GGC	AAG	CTT	GAA	TCT	AAA	TTA	TCA	GTC	ATA	AGA	AAT	TTG	AAT	48
	Tyr	Phe	Gly	Lys	Leu	Glu	Ser	Lys	Leu	Ser	Val	Ile	Arg	Asn	Leu	Asn	
	1				5				10						15		
	GAC	CAA	GTT	CTC	TTC	ATT	GAC	CAA	GGA	AAT	CGG	CCT	CTA	TTT	GAA	GAT	96
	Asp	Gln	Val	Ile	Phe	Ile	Asp	Gln	Gly	Asn	Arg	Pro	Leu	Phe	Glu	Asp	
				20					25						30		
10	ATG	ACT	GAT	TCT	GAC	TCT	AGA	GAT	AAT	GCA	CCC	CGG	ACC	ATA	TTT	ATT	144
	Met	Thr	Asp	Ser	Asp	Ser	Arg	Asp	Asn	Ala	Pro	Arg	Thr	Ile	Phe	Ile	
				35					40						45		
	ATA	AGT	ATG	TAT	AAA	GAT	AGC	CAG	CCT	AGA	GGT	ATG	GCT	GTA	ACT	ATC	192
	Ile	Ser	Met	Tyr	Lys	Asp	Ser	Gln	Pro	Arg	Gly	Met	Ala	Val	Thr	Ile	
				50					55						60		
15	TCT	GTG	AAG	TCT	GAG	AAA	ATT	TCA	ACT	CTC	TCC	TGT	GAG	AAC	AAA	ATT	240
	Ser	Val	Lys	Ser	Glu	Lys	Ile	Ser	Thr	Leu	Ser	Cys	Glu	Asn	Lys	Ile	
					70										80		
	ATT	TCC	TTT	AAG	GAA	ATG	AAT	CCT	CCT	GAT	AAC	ATC	AAG	GAT	ACA	AAA	288
	Ile	Ser	Phe	Lys	Glu	Met	Asn	Pro	Pro	Asp	Asn	Ile	Lys	Asp	Thr	Lys	
					85										95		
20	AGT	GAC	ATC	ATA	TTC	TTT	CAG	AGA	AGT	GTC	CCA	GGA	CAT	GAT	AAT	AAG	336
	Ser	Asp	Ile	Ile	Phe	Phe	Gln	Arg	Ser	Val	Pro	Gly	His	Asp	Asn	Lys	
				100											110		
	ATG	CAA	TTT	GAA	TCT	TCA	TCA	TAC	GAA	GGA	TAC	TTT	CTA	GCT	TGT	GAA	384
	Met	Gln	Phe	Glu	Ser	Ser	Ser	Tyr	Glu	Gly	Tyr	Phe	Leu	Ala	Cys	Glu	
				115					120						125		
25	AAA	GAG	AGA	GAC	CTT	TTT	AAA	CTC	ATT	TTG	AAA	AAA	GAG	GAT	GAA	TTG	432
	Lys	Glu	Arg	Asp	Leu	Phe	Lys	Leu	Ile	Leu	Lys	Lys	Glu	Asp	Glu	Leu	
				130					135						140		
	GGG	GAT	AGA	TCT	ATA	ATG	TTC	ACT	GTT	CAA	AAC	GAA	GAC				471
	Gly	Asp	Arg	Ser	Ile	Met	Phe	Thr	Val	Gln	Asn	Glu	Asp				
30																	
	145					150					155						

## SEQ ID NO: 17:

35	TAC	TTT	GGC	AAG	CTT	GAA	TCT	AAA	TTA	TCA	GTC	ATA	AGA	AAT	TTG	AAT	48
	Tyr	Phe	Gly	Lys	Leu	Glu	Ser	Lys	Leu	Ser	Val	Ile	Arg	Asn	Leu	Asn	
	1				5				10						15		
	GAC	CAA	GTT	CTC	TTC	ATT	GAC	CAA	GGA	AAT	CGG	CCT	CTA	TTT	GAA	GAT	96
	Asp	Gln	Val	Leu	Phe	Ile	Asp	Gln	Asn	Arg	Pro	Leu	Phe	Glu	Asp		
				20					25						30		
40	ATG	ACT	GAT	TCT	GAC	TGT	AGA	GAT	AAT	GCA	CCC	CGG	ACC	ATA	TTT	ATT	144
	Met	Thr	Asp	Ser	Asp	Cys	Arg	Asp	Asn	Ala	Pro	Arg	Thr	Ile	Phe	Ile	
				35					40						45		
	ATA	AGT	ATG	TAT	AAA	GAT	AGC	CAG	CCT	AGA	GGT	ATG	GCT	GTA	ACT	ATC	192
	Ile	Ser	Met	Tyr	Lys	Asp	Ser	Gln	Pro	Arg	Gly	Met	Ala	Val	Thr	Ile	
				50					55						60		
45	TCT	GTG	AAG	TCT	GAG	AAA	ATT	TCA	ACT	CTC	TCC	TGT	GAG	AAC	AAA	ATT	240
	Ser	Val	Lys	Ser	Glu	Lys	Ile	Ser	Thr	Leu	Ser	Cys	Glu	Asn	Lys	Ile	
					70										80		
	ATT	TCC	TTT	AAG	GAA	ATG	AAT	CCT	CCT	GAT	AAC	ATC	AAG	GAT	ACA	AAA	288
	Ile	Ser	Phe	Lys	Glu	Met	Asn	Pro	Pro	Asp	Asn	Ile	Lys	Asp	Thr	Lys	
					85										95		
50	AGT	GAC	ATC	ATA	TTC	TTT	CAG	AGA	AGT	GTC	CCA	GGA	CAT	GAT	AAT	AAG	336
	Ser	Asp	Ile	Ile	Phe	Phe	Gln	Arg	Ser	Val	Pro	Gly	His	Asp	Asn	Lys	
				100											110		
	ATG	CAA	TTT	GAA	TCT	TCA	TCA	TAC	GAA	GGA	TAC	TTT	CTA	GCT	TCT	GAA	384

55

## EP 0 845 530 A2

	Met	Gln	Phe	Glu	Ser	Ser	Ser	Tyr	Glu	Gly	Tyr	Phe	Leu	Ala	Ser	Glu	
			115					120					125				
5	AAA	GAG	AGA	GAC	CTT	TTT	AAA	CTC	ATT	TTG	AAA	AAA	GAG	GAT	GAA	TTG	432
	Lys	Glu	Arg	Asp	Leu	Phe	Lys	Leu	Ile	Leu	Lys	Lys	Glu	Asp	Glu	Leu	
			130				135					140					
	GGG	GAT	AGA	TCT	ATA	ATG	TTC	ACT	GTT	CAA	AAC	GAA	GAC				471
	Gly	Asp	Arg	Ser	Ile	Met	Phe	Thr	Val	Gln	Asn	Glu	Asp				
	145					150					155						
10	SEQ ID NO: 18:																
	TAC	TTT	GGC	AAG	CTT	GAA	TCT	AAA	TTA	TCA	GTC	ATA	AGA	AAT	TTG	AAT	48
	Tyr	Phe	Gly	Lys	Leu	Glu	Ser	Lys	Leu	Ser	Val	Ile	Arg	Asn	Leu	Asn	
	1				5				10						15		
15	GAC	CAA	GTT	CTC	TTC	ATT	GAC	CAA	GGA	AAT	CGG	CCT	CTA	TTT	GAA	GAT	96
	Asp	Gln	Val	Leu	Phe	Ile	Asp	Gln	Gly	Asn	Arg	Pro	Leu	Phe	Glu	Asp	
				20					25					30			
	ATG	ACT	GAT	TCT	GAC	TCT	AGA	GAT	AAT	GCA	CCC	CGG	ACC	ATA	TTT	ATT	144
	Met	Thr	Asp	Ser	Asp	Ser	Arg	Asp	Asn	Ala	Pro	Arg	Thr	Ile	Phe	Ile	
				35				40					45				
20	ATA	AGT	ATG	TAT	AAA	GAT	AGC	CAG	CCT	AGA	GGT	ATG	GCT	GTA	ACT	ATC	192
	Ile	Ser	Met	Tyr	Lys	Asp	Ser	Gln	Pro	Arg	Gly	Met	Ala	Val	Thr	Ile	
				50			55					60					
	TCT	GTG	AAG	TCT	GAG	AAA	ATT	TCA	ACT	CTC	TCC	TGT	GAG	AAC	AAA	ATT	240
	Ser	Val	Lys	Ser	Glu	Lys	Ile	Ser	Thr	Leu	Ser	Cys	Glu	Asn	Lys	Ile	
				65		70				75				80			
25	ATT	TCC	TTT	AAG	GAA	ATG	AAT	CCT	CCT	GAT	AAC	ATC	AAG	GAT	ACA	AAA	288
	Ile	Ser	Phe	Lys	Glu	Met	Asn	Pro	Pro	Asp	Asn	Ile	Lys	Asp	Thr	Lys	
				85					90					95			
	AGT	GAC	ATC	ATA	TTC	TTT	CAG	AGA	AGT	GTC	CCA	GGA	CAT	GAT	AAT	AAG	336
	Ser	Asp	Ile	Ile	Phe	Phe	Gln	Arg	Ser	Val	Pro	Gly	His	Asp	Asn	Lys	
				100					105					110			
30	ATG	CAA	TTT	GAA	TCT	TCA	TCA	TAC	GAA	GGA	TAC	TTT	CTA	GCT	TCT	GAA	384
	Met	Gln	Phe	Glu	Ser	Ser	Ser	Tyr	Glu	Gly	Tyr	Phe	Leu	Ala	Ser	Glu	
				115				120					125				
	AAA	GAG	AGA	GAC	CTT	TTT	AAA	CTC	ATT	TTG	AAA	AAA	GAG	GAT	GAA	TTG	432
	Lys	Glu	Arg	Asp	Leu	Phe	Lys	Leu	Ile	Leu	Lys	Lys	Glu	Asp	Glu	Leu	
35				130			135					140					
	GGG	GAT	AGA	TCT	ATA	ATG	TTC	ACT	GTT	CAA	AAC	GAA	GAC				471
	Gly	Asp	Arg	Ser	Ile	Met	Phe	Thr	Val	Gln	Asn	Glu	Asp				
	145					150					155						
40	SEQ ID NO: 19:																
	TAC	TTT	GGC	AAG	CTT	GAA	TCT	AAA	TTA	TCA	GTC	ATA	AGA	AAT	TTG	AAT	48
	Tyr	Phe	Gly	Lys	Leu	Glu	Ser	Lys	Leu	Ser	Val	Ile	Arg	Asn	Leu	Asn	
	1				5				10						15		
45	GAC	CAA	GTT	CTC	TTC	ATT	GAC	CAA	GGA	AAT	CGG	CCT	CTA	TTT	GAA	GAT	96
	Asp	Gln	Val	Leu	Phe	Ile	Asp	Gln	Gly	Asn	Arg	Pro	Leu	Phe	Glu	Asp	
				20					25				30				
	ATG	ACT	GAT	TCT	GAC	TCT	AGA	GAT	AAT	GCA	CCC	CGG	ACC	ATA	TTT	ATT	144
	Met	Thr	Asp	Ser	Asp	Ser	Arg	Asp	Asn	Ala	Pro	Arg	Thr	Ile	Phe	Ile	
				35				40					45				
50	ATA	AGT	ATG	TAT	AAA	GAT	AGC	CAG	CCT	AGA	GGT	ATG	GCT	GTA	ACT	ATC	192
	Ile	Ser	Met	Tyr	Lys	Asp	Ser	Gln	Pro	Arg	Gly	Met	Ala	Val	Thr	Ile	
				50			55					60					
	TCT	GTG	AAG	TCT	GAG	AAA	ATT	TCA	ACT	CTC	TCC	TCT	GAG	AAC	AAA	ATT	240
55																	

EP 0 845 530 A2

	Ser	Val	Lys	Ser	Glu	Lys	Ile	Ser	Thr	Leu	Ser	Ser	Glu	Asn	Lys	Ile	
	65				70					75						80	
	ATT	TCC	TTT	AAG	GAA	ATG	AAT	CCT	CCT	GAT	AAC	ATC	AAG	GAT	ACA	AAA	288
5	Ile	Ser	Phe	Lys	Glu	Met	Asn	Pro	Pro	Asp	Asn	Ile	Lys	Asp	Thr	Lys	
				85						90					95		
	AGT	GAC	ATC	ATA	TTC	TTT	CAG	AGA	AGT	GTC	CCA	GGA	CAT	GAT	AAT	AAG	336
	Ser	Asp	Ile	Ile	Phe	Phe	Gln	Arg	Ser	Val	Pro	Gly	His	Asp	Asn	Lys	
				100					105					110			
10	ATG	CAA	TTT	GAA	TCT	TCA	TCA	TAC	GAA	GGA	TAC	TTT	CTA	GCT	TCT	GAA	384
	Met	Gln	Phe	Glu	Ser	Ser	Ser	Tyr	Glu	Gly	Tyr	Phe	Leu	Ala	Ser	Glu	
				115				120					125				
	AAA	GAG	AGA	GAC	CTT	TTT	AAA	CTC	ATT	TTG	AAA	AAA	GAG	GAT	GAA	TTG	432
	Lys	Glu	Arg	Asp	Leu	Phe	Lys	Leu	Ile	Leu	Lys	Lys	Glu	Asp	Glu	Leu	
		130					135					140					
15	GGG	GAT	AGA	TCT	ATA	ATG	TTC	ACT	GTT	CAA	AAC	GAA	GAC				471
	Gly	Asp	Arg	Ser	Ile	Met	Phe	Thr	Val	Gln	Asn	Glu	Asp				
	145					150					155						

SEQ ID NO: 20:

20	TAC	TTT	GGC	AAG	CTT	GAA	TCT	AAA	TTA	TCA	GTC	ATA	AGA	AAT	TTG	AAT	48
	Tyr	Phe	Gly	Lys	Leu	Glu	Ser	Lys	Leu	Ser	Val	Ile	Arg	Asn	Leu	Asn	
	1				5					10					15		
	GAC	CAA	GTT	CTC	TTC	ATT	GAC	CAA	GGA	AAT	CGG	CCT	CTA	TTT	GAA	GAT	96
	Asp	Gln	Val	Leu	Phe	Ile	Asp	Gln	Gly	Asn	Arg	Pro	Leu	Phe	Glu	Asp	
				20					25					30			
25	ATG	ACT	GAT	TCT	GAC	TCT	AGA	GAT	AAT	GCA	CCC	CGG	ACC	ATA	TTT	ATT	144
	Met	Thr	Asp	Ser	Asp	Ser	Arg	Asp	Asn	Ala	Pro	Arg	Thr	Ile	Phe	Ile	
				35				40					45				
	ATA	AGT	ATG	TAT	AAA	GAT	AGC	CAG	CCT	AGA	GGT	ATG	GCT	GTA	ACT	ATC	192
	Ile	Ser	Met	Tyr	Lys	Asp	Ser	Gln	Pro	Arg	Gly	Met	Ala	Val	Thr	Ile	
				50			55				60						
30	TCT	GTG	AAG	TCT	GAG	AAA	ATT	TCA	ACT	CTC	TCC	GCT	GAG	AAC	AAA	ATT	240
	Ser	Val	Lys	Ser	Glu	Lys	Ile	Ser	Thr	Leu	Ser	Ala	Glu	Asn	Lys	Ile	
					70					75					80		
	ATT	TCC	TTT	AAG	GAA	ATG	AAT	CCT	CCT	GAT	AAC	ATC	AAG	GAT	ACA	AAA	288
35	Ile	Ser	Phe	Lys	Glu	Met	Asn	Pro	Pro	Asp	Asn	Ile	Lys	Asp	Thr	Lys	
				85						90				95			
	AGT	GAC	ATC	ATA	TTC	TTT	CAG	AGA	AGT	GTC	CCA	GGA	CAT	GAT	AAT	AAG	336
	Ser	Asp	Ile	Ile	Phe	Phe	Gln	Arg	Ser	Val	Pro	Gly	His	Asp	Asn	Lys	
				100					105					110			
40	ATG	CAA	TTT	GAA	TCT	TCA	TCA	TAC	GAA	GGA	TAC	TTT	CTA	GCT	TGT	GAA	384
	Met	Gln	Phe	Glu	Ser	Ser	Ser	Tyr	Glu	Gly	Tyr	Phe	Leu	Ala	Cys	Glu	
				115				120					125				
	AAA	GAG	AGA	GAC	CTT	TTT	AAA	CTC	ATT	TTG	AAA	AAA	GAG	GAT	GAA	TTG	432
	Lys	Glu	Arg	Asp	Leu	Phe	Lys	Leu	Ile	Leu	Lys	Lys	Glu	Asp	Glu	Leu	
		130					135					140					
45	GGG	GAT	AGA	TCT	ATA	ATG	TTC	ACT	GTT	CAA	AAC	GAA	GAC				471
	Gly	Asp	Arg	Ser	Ile	Met	Phe	Thr	Val	Gln	Asn	Glu	Asp				
	145					150					155						

SEQ ID NO: 21:

50	TAC	TTT	GGC	AAG	CTT	GAA	TCT	AAA	TTA	TCA	GTC	ATA	AGA	AAT	TTG	AAT	48
	Tyr	Phe	Gly	Lys	Leu	Glu	Ser	Lys	Leu	Ser	Val	Ile	Arg	Asn	Leu	Asn	
	1				5					10					15		
	GAC	CAA	GTT	CTC	TTC	ATT	GAC	CAA	GGA	AAT	CGG	CCT	CTA	TTT	GAA	GAT	96

55

EP 0 845 530 A2

	Asp	Gln	Val	Leu	Phe	Ile	Asp	Gln	Gly	Asn	Arg	Pro	Leu	Phe	Glu	Asp	
				20					25					30			
5	ATG	ACT	GAT	TCT	GAC	TCT	AGA	GAT	AAT	GCA	CCC	CGG	ACC	ATA	TTT	ATT	144
	Met	Thr	Asp	Ser	Asp	Ser	Arg	Asp	Asn	Ala	Pro	Arg	Thr	Ile	Phe	Ile	
			35					40					45				
	ATA	AGT	ATG	TAT	AAA	GAT	AGC	CAG	CCT	AGA	GGT	ATG	GCT	GTA	ACT	ATC	192
	Ile	Ser	Met	Tyr	Lys	Asp	Ser	Gln	Pro	Arg	Gly	Met	Ala	Val	Thr	Ile	
			50					55				60					
10	TCT	GTG	AAG	TCT	GAG	AAA	ATT	TCA	ACT	CTC	TCC	GCT	GAG	AAC	AAA	ATT	240
	Ser	Val	Lys	Ser	Glu	Lys	Ile	Ser	Thr	Leu	Ser	Ala	Glu	Asn	Lys	Ile	
			65				70				75					80	
	ATT	TCC	TTT	AAG	GAA	ATG	AAT	CCT	CCT	GAT	AAC	ATC	AAG	GAT	ACA	AAA	288
	Ile	Ser	Phe	Lys	Glu	Met	Asn	Pro	Pro	Asp	Asn	Ile	Lys	Asp	Thr	Lys	
					85					90					95		
15	AGT	GAC	ATC	ATA	TTC	TTT	CAG	AGA	AGT	GTC	CCA	GGA	CAT	GAT	AAT	AAG	336
	Ser	Asp	Ile	Ile	Phe	Phe	Gln	Arg	Ser	Val	Pro	Gly	His	Asp	Asn	Lys	
				100					105					110			
	ATG	CAA	TTT	GAA	TCT	TCA	TCA	TAC	GAA	GGA	TAC	TTT	CTA	GCT	TCT	GAA	384
	Met	Gln	Phe	Glu	Ser	Ser	Ser	Tyr	Glu	Gly	Tyr	Phe	Leu	Ala	Ser	Glu	
				115				120					125				
20	AAA	GAG	AGA	GAC	CTT	TTT	AAA	CTC	ATT	TTG	AAA	AAA	GAG	GAT	GAA	TTG	432
	Lys	Glu	Arg	Asp	Leu	Phe	Lys	Leu	Ile	Leu	Lys	Lys	Glu	Asp	Glu	Leu	
			130				135					140					
	GGG	GAT	AGA	TCT	ATA	ATG	TTC	ACT	GTT	CAA	AAC	GAA	GAC				471
	Gly	Asp	Arg	Ser	Ile	Met	Phe	Thr	Val	Gln	Asn	Glu	Asp				
25	145					150				155							

SEQ ID NO: 22:

	AAC	TTT	GGC	CGA	CTT	CAC	GCT	ACA	ACC	GCA	GTA	ATA	CGG	AAT	ATA	AAT	48
30	Asn	Phe	Gly	Arg	Leu	His	Ala	Thr	Thr	Ala	Val	Ile	Arg	Asn	Ile	Asn	
	1				5					10				15			
	GAC	CAA	GTT	CTC	TTC	GTT	GAC	AAA	AGA	CAG	CCT	GTG	TTC	GAG	GAT	ATG	96
	Asp	Gln	Val	Leu	Phe	Val	Asp	Lys	Arg	Gln	Pro	Val	Phe	Glu	Asp	Met	
				20					25					30			
35	ACT	GAT	ATT	GAT	CAA	AGT	GCC	AGT	GAA	CCC	CAG	ACC	AGA	CTG	ATA	ATA	144
	Thr	Asp	Ile	Asp	Gln	Ser	Ala	Ser	Glu	Pro	Gln	Thr	Arg	Leu	Ile	Ile	
			35				40					45					
	TAC	ATG	TAC	AAA	GAC	AGT	GAA	GTA	AGA	GGA	CTG	GCT	GTG	ACC	CTC	TCT	192
	Tyr	Met	Tyr	Lys	Asp	Ser	Glu	Val	Arg	Gly	Leu	Ala	Val	Thr	Leu	Ser	
			50				55				60						
40	GTG	AAG	GAT	AGT	AAA	ATG	TCT	ACC	CTC	TCC	TGT	AAG	AAC	AAG	ATC	ATT	240
	Val	Lys	Asp	Ser	Lys	Met	Ser	Thr	Leu	Ser	Cys	Lys	Asn	Lys	Ile	Ile	
			65				70				75					80	
	TCC	TTT	GAG	GAA	ATG	GAT	CCA	CCT	GAA	AAT	ATT	GAT	GAT	ATA	CAA	AGT	288
	Ser	Phe	Glu	Glu	Met	Asp	Pro	Pro	Glu	Asn	Ile	Asp	Asp	Ile	Gln	Ser	
					85				90					95			
45	GAT	CTC	ATA	TTC	TTT	CAG	AAA	CGT	GTT	CCA	GGA	CAC	AAC	AAG	ATG	GAG	336
	Asp	Leu	Ile	Phe	Phe	Gln	Lys	Arg	Val	Pro	Gly	His	Asn	Lys	Met	Glu	
				100				105						110			
	TTT	GAA	TCT	TCA	CTG	TAT	GAA	GGA	CAC	TTT	CTT	GCT	TGC	CAA	AAG	GAA	384
	Phe	Glu	Ser	Ser	Leu	Tyr	Glu	Gly	His	Phe	Leu	Ala	Cys	Gln	Lys	Glu	
			115				120					125					
50	GAT	GAT	GCT	TTC	AAA	CTC	ATT	CTG	AAA	AAA	AAG	GAT	GAA	AAT	GGG	GAT	432
	Asp	Asp	Ala	Phe	Lys	Leu	Ile	Leu	Lys	Lys	Lys	Asp	Glu	Asn	Gly	Asp	
			130				135				140						
	AAA	TCT	GTA	ATG	TTC	ACT	CTC	ACT	AAC	TTA	CAT	CAA	AGT				471

55

Lys Ser Val Met Phe Thr Leu Thr Asn Leu His Gln Ser  
145 150 155

SEQ ID NO: 23:

5 AAC TTT GGC CGA CTT CAC TGT ACA ACC GCA GTA ATA CGG AAT ATA AAT 48  
Asn Phe Gly Arg Leu His Cys Thr Thr Ala Val Ile Arg Asn Ile Asn  
1 5 10 15  
10 GAC CAA GTT CTC TTC GTT GAC AAA AGA CAG CCT GTG TTC GAG GAT ATG 96  
Asp Gln Val Leu Phe Val Asp Lys Arg Gln Pro Val Phe Glu Asp Met  
20 25 30  
ACT GAT ATT GAT CAA AGT GCC AGT GAA CCC CAG ACC AGA CTG ATA ATA 144  
Thr Asp Ile Asp Gln Ser Ala Ser Glu Pro Gln Thr Arg Leu Ile Ile  
35 40 45  
15 TAC ATG TAC AAA GAC AGT GAA GTA AGA GGA CTG GCT GTG ACC CTC TCT 192  
Tyr Met Tyr Lys Asp Ser Glu Val Arg Gly Leu Ala Val Thr Leu Ser  
50 55 60  
GTG AAG GAT AGT AAA ATG TCT ACC CTC TCC TGT AAG AAC AAG ATC ATT 240  
Val Lys Asp Ser Lys Met Ser Thr Leu Ser Cys Lys Asn Lys Ile Ile  
65 70 75 80  
20 TCC TTT GAG GAA ATG GAT CCA CCT GAA AAT ATT GAT GAT ATA CAA AGT 288  
Ser Phe Glu Glu Met Asp Pro Pro Glu Asn Ile Asp Asp Ile Gln Ser  
85 90 95  
GAT CTC ATA TTC TTT CAG AAA CGT GTT CCA GGA CAC AAC AAG ATG GAG 336  
Asp Leu Ile Phe Phe Gln Lys Arg Val Pro Gly His Asn Lys Met Glu  
100 105 110  
25 TTT GAA TCT TCA CTG TAT GAA GGA CAC TTT CTT GCT AGC CAA AAG GAA 384  
Phe Glu Ser Ser Leu Tyr Glu Gly His Phe Leu Ala Ser Gln Lys Glu  
115 120 125  
GAT GAT GCT TTC AAA CTC ATT CTG AAA AAA AAG GAT GAA AAT GGG GAT 432  
Asp Asp Ala Phe Lys Leu Ile Leu Lys Lys Lys Asp Glu Asn Gly Asp  
130 135 140  
30 AAA TCT GTA ATG TTC ACT CTC ACT AAC TTA CAT CAA AGT. 471  
Lys Ser Val Met Phe Thr Leu Thr Asn Leu His Gln Ser  
145 150 155

35 11. The DNA of claim 9, which contains the nucleotide sequence of SEQ ID NO:24 at the 5'-terminus.

SEQ ID NO: 24:

40 ATGGCCTTGA CCTTTGCTTT ACTGGTGGCC CTCCTGGTGC TCAGCTGCAA GTCAAGCTGC 60  
TCTGTGGGC 69

12. The DNA of claim 9, which is inserted into an autonomously replicable vector.

45 13. The DNA of claim 9, which is introduced into an appropriate host.

14. The DNA of claim 13, wherein said host is a cell selected from the group consisting of mammalian-epithelial, interstitial, and -hematopoietic cells.

50 15. A process for producing a polypeptide, which comprises the steps of:

culturing a cell containing a DNA encoding the polypeptide of claim 1, obtainable by introducing the DNA into an appropriate host, to produce a polypeptide, and  
collecting the produced polypeptide from the resulting culture.

55

16. The process of claim 15, wherein said host is a cell selected from the group consisting of mammalian-epithelial, -interstitial, and -hematopoietic cells.

17. The process of claim 15, wherein said polypeptide is collected by one or more techniques selected from the group consisting of dialysis, salting out, filtration, concentration, fractional precipitation, ion-exchange chromatography, isoelectric focusing chromatography, hydrophobic chromatography, reversed phase chromatography, affinity chromatography, gel electrophoresis, and isoelectric focusing gel electrophoresis.

5

18. The process of claim 15, wherein said polypeptide is collected by an immunoaffinity chromatography using a monoclonal antibody.

19. An agent for susceptible diseases, which contains the polypeptide of claim 1 as an effective ingredient.

10

20. The agent of claim 19, which additionally contains interleukin 2.

21. The agent of claim 19, which contains a serum albumin, gelatin, a saccharide, or a buffer as a stabilizer.

15

22. The agent of claim 19, which is in the form of an antitumor agent.

23. The agent of claim 22, which is in the form of an antitumor immunotherapeutic agent.

24. The agent of claim 19, which is in the form of an antiviral agent.

20

25. The agent of claim 19, which is in the form of an antimicrobial agent.

26. The agent of claim 19, which is in the form of an anti-immunopathic agent.

25

27. The agent of claim 26, which additionally contains interleukin 12.

28. The agent of claim 26, which is for treating atopic diseases.

30


35

40


45

50

55




**FIG. 1**



**FIG. 2**





Note: In the figure, the symbol "○—○" shows the time course upon the activity of a wild-type polypeptide; and the symbols "▼—▼", "▲—▲", "▽—▽", "◇—◇", "●—●", "■—■", and "△—△" show the time course upon the activity of the present polypeptides obtained by the methods in Examples A-1 to A-7, respectively.

FIG. 3




FIG. 4




FIG. 5




FIG. 6







FIG. 7




**FIG. 8**




**FIG. 9**



**FIG. 10**




**FIG. 11**



Note: In the figure, the symbol "■—■" shows the time course upon the activity of a wild-type polypeptide; and the symbols "□—□" and "◆—◆" show the time course upon the activity of the present polypeptides obtained by the methods in Examples A-8 and A-9, respectively.

FIG. 12



**FIG. 13**